Strategic Consolidation in European HealthTech: Legrand Care’s Acquisition of Axel Health Transaction Architecture and Financial Overview On July 29th, 2026, Legrand Care, the specialised connected healthcare technology division of French electrical and digital building infrastructure multinational Legrand SA, finalised the acquisition of Finnish digital patient flow management provider Axel Health Oy. The transaction involved the complete buy-out of the equity stake held by Stockholm-based growth private equity firm Standout Capital, alongside minority holdings retained by key founders and management. Founded in 2008 and headquartered in Espoo, Finland, Axel Health has grown into a dominant provider of workflow software for acute public health networks, regional healthcare service authorities, and social care providers across the Nordic region. Financial disclosures indicate that Axel Health generated pro forma revenues of approximately €9 million in fiscal year 2025, yielding an EBITDA between €2.5 million and €3.0 million. Standout Capital originally entered Axel Health via its Standout Capital I fund in May 2019. Over the course of Standout's seven-year investment lifecycle, Axel Health expanded its market leadership across Finland and Sweden, achieving a threefold increase in annual recurring revenue and a fourfold expansion in EBITDAC. This sustained expansion was achieved despite widespread structural budget constraints across European public health systems. The transaction was structured as an all-cash strategic acquisition designed to allow rapid operational integration into Legrand Care's digital platform. Sell-side M&A advisory was managed exclusively by MCF Corporate Finance, with a transaction team comprising Erik Pettersson, Robert Sällström, Johanna Tell, Amos Aaltio, and Jakob Scott. Legal representation for Axel Health and its selling equity holders was provided by Avance Attorneys. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Transaction Parameter Details & Financial Metrics Sources Transaction Close Date July 29th, 2026 Various Acquirer Entity Legrand Care (Division of Legrand SA, Euronext Paris: LR) Various Target Entity Axel Health Oy (Espoo, Finland) Various Seller Entity Standout Capital (Standout Capital I Fund) & Minority Shareholders Various Transaction Structure Undisclosed valuation; all-cash strategic buy-out Various Target FY25 Pro Forma Revenue ~€9.0 Million Various Target FY25 Pro Forma EBITDA €2.5 Million – €3.0 Million Various Private Equity Value Creation (2019–2026) 3x Recurring Revenue Growth; 4x EBITDAC Growth Various Sell-Side M&A Advisor MCF Corporate Finance Various Sell-Side Legal Counsel Avance Attorneys Various Target Platform Capabilities: Axel Health’s Patient Flow Ecosystem Axel Health operates as a software provider with a team of approximately 46 employees across Finland and Sweden. Its technological architecture addresses operational bottlenecks in high-density medical environments, including major university hospitals, primary health clinics, emergency care centers, and specialised outpatient facilities. Axel Health's primary value proposition centres on eliminating physical administrative queues, maximising facility usage rates, and automating patient transition communication between care settings. The company's core platform is organised into three interconnected software environments that digitise the patient journey: Axel Encounter forms the frontend engagement and check-in architecture. Operating via self-service touch-screen kiosks, mobile devices, and digital signage, Encounter handles patient check-in, real-time wayfinding, clinical questionnaire collection, and payment processing. The system reduces patient check-in routines to an average of 17 seconds, achieving administrative automation rates exceeding 90% and alleviating reception desk congestion. In paediatric clinical settings, Encounter incorporates customised features such as digital avatar guides to lower stress levels for young patients. Axel Planner functions as the centralised shift management, facility scheduling and operational planning engine. Planner merges room-booking requirements across disparate medical units into a single synchronised interface, preventing scheduling conflicts and optimising clinical space usage. By matching clinical staff shift patterns against forecasted patient visit volumes, Planner reduces administrative overhead for doctors, nurses and unit secretaries. Uoma operates as a patient transfer coordination module. Originally developed by Unitary Healthcare Oy and acquired by Axel Health in mid-2024, Uoma replaces unstructured telephone communications with real-time location tracking and structured digital messaging during patient transfers. The software accelerates placement identification for follow-up care, facilitating smoother transfers between acute care hospitals and municipal social services. Software Module Core Functionality Primary Operational Impact Axel Encounter Self-service kiosks, mobile check-in, digital wayfinding, payment automation, pediatric avatars Reduces check-in times to 17 seconds; achieves >90% administrative automation rate Axel Planner Resource allocation, shift optimization, shared room scheduling, spatial analytics Eliminates overlapping facility bookings; optimizes staff allocation against patient volume Uoma Inter-unit patient transfer coordination, structured messaging, placement tracking Removes phone communication bottlenecks; accelerates transition from acute to social care Platform Ecosystem Unified patient journey execution suite Delivers >20% savings in personnel costs; generates up to 4.5x return on software investment Corporate Transformation: Legrand Care’s M&A Strategy Legrand Care operates as the dedicated healthtech and assisted living division of Legrand SA, an industrial group with global revenues of €6.1 Billion in 2020 and operations in over 90 countries. Legrand Care was formally created in November 2021 under CEO Chris Dodd, bringing together five established European telecare and health technology providers: Aid Call, Tynetec, Jontek (United Kingdom), Neat (Spain/Sweden), and Intervox (France). Executive management was further consolidated with Arturo Pérez Kramer as Deputy CEO and Caroline Mouminoux as Sales Director. Historically focused on physical infrastructure, including wireless nurse call hardware (Touchsafe Pro), alarm monitoring platforms (Answerlink) and connected telecare hubs (NOVO and NOVO Go), Legrand Care has faced shifting dynamics in European healthcare. Structural demographic aging, rising chronic disease prevalence and nursing shortages across Europe have driven demand away from standalone hardware devices toward cloud-native software ecosystems capable of managing care coordination across home, residential and hospital environments. To address these market demands, Legrand Care launched a programmatic M&A sequence across Europe: In 2024, Legrand Care acquired Dutch digital care platform Enovation from Main Capital Partners. Enovation provided foundational capabilities in clinical data integration, inter-professional messaging, and secure healthcare communication infrastructure. In 2025, Legrand Care acquired Netherlands-based health analytics provider Performation from Gilde Healthcare. Performation contributed business intelligence tools, healthcare delivery analytics, and operational planning software. The 2026 acquisition of Axel Health represents the third major transaction in this expansion sequence. Axel Health supplies the patient-facing engagement layer, real-time hospital patient flow management and inter-unit transfer coordination that links hospital operations directly with community care infrastructure. Strategic Asset Acquisition Year Divesting Entity Strategic Capabilities Added Source Enovation 2024 Main Capital Partners Secure clinical data integration, inter-professional communication, healthcare interoperability Various Performation 2025 Gilde Healthcare Healthcare business intelligence, operational analytics, financial optimization platforms Various Axel Health 2026 Standout Capital Real-time patient flow management (PFM), automated scheduling, patient transfer systems Various Strategic Rationale and Ecosystem Synergies The integration of Axel Health into Legrand Care delivers strategic advantages across market expansion, product cross-selling, and competitive positioning: The Nordic region represents one of Europe's most digitally mature public healthcare markets, characterised by single-payer structures, widespread Electronic Health Record adoption, and high public health investments. Axel Health maintains deep customer relationships across Finnish Wellbeing Services Counties and Swedish healthcare regions. Acquiring Axel Health gives Legrand Care an established commercial network to cross-sell its wider software portfolio across Northern Europe. A primary friction point in European healthcare delivery occurs during patient transitions between acute hospital care, post-acute rehab, and home care. Uncoordinated transfer processes often lead to extended hospital stays and bed-blocking. Integrating Axel Health’s Uoma transfer tracking and Planner resource tools with Enovation’s messaging hub and Legrand Care’s NOVO Go home monitoring devices creates a unified care management pathway. Hospital discharge planners can schedule a patient's transition home, order post-discharge social care services, and provision remote telecare monitoring within a single workflow. 3 Combining building electrical infrastructure, nurse call hardware, clinical integration software, and patient flow management positions Legrand Care more directly against healthcare conglomerates like Philips Healthcare Solutions and Siemens Healthineers. While traditional competitors focus primarily on medical devices or basic building management, Legrand Care offers an enterprise platform bridging physical infrastructure with healthcare software. Executive commentary confirms this strategic alignment. Chris Dodd, CEO of Legrand Care, highlighted that Axel Health has established a strong position in patient flow management that complements Legrand Care's digital platform. Ilari Laaksonen, CEO of Axel Health, noted that joining Legrand Care presents opportunities for customers, employees, and partners by accelerating the development of patient flow and engagement software within a global corporate organisation. Erik Wästlund, Co-founder of Standout Capital, emphasised that the company's financial growth during Standout's ownership period demonstrates the underlying market demand for workflow optimisation tools. Post-Merger Integration Dynamics and Risk Landscape Realising the expected return on investment will require active management of several post-merger integration risks: Harmonising Axel Health’s technology stack with the existing Enovation and Performation software platforms requires ongoing development work. Establishing standardised Application Programming Interfaces (APIs) and unified data models is necessary to enable real-time communication between Axel Encounter check-in kiosks, Axel Planner booking engines, Enovation clinical messaging hubs, and Answerlink monitoring platforms. Expanding Axel Health’s platform outside its core Nordic markets into the United Kingdom, France and Central Europe introduces regulatory and localisation challenges. Healthcare purchasing structures, patient privacy laws and hospital operational models vary significantly across European jurisdictions. Legrand Care must adapt Axel Health's software to meet local regulatory frameworks and integration standards without incurring excessive customisation costs. Preserving Axel Health’s customer-centric culture and agile product iteration speed while integrating into a large industrial enterprise represents a key organizational objective. Management must maintain key engineering talent and safeguard software development velocity to ensure the business remains competitive against specialised healthtech vendors. Outlook and Industry Implications Legrand Care’s acquisition of Axel Health reflects a broader ongoing consolidation trend within the European HealthTech market. As public healthcare systems grapple with demographic pressure, fiscal constraints, and staffing challenges, demand is accelerating for software platforms that improve operational productivity, shorten patient stay durations, and streamline administrative workflows. By successfully uniting physical infrastructure, telecare hardware, and a connected software stack comprising Enovation, Performation, and Axel Health, Legrand Care has established an integrated care management platform. This transaction positions the company to capture growing market share across European healthcare and social care sectors as health authorities increasingly transition toward unified, technology-enabled care ecosystems. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

The Enterprise Identity Paradigm Shift: How Five Transactions in Seven Days Priced AI Agent Governance The enterprise security landscape experienced an unprecedented structural realignment during the week of July 27th, 2026. While public market attention was dominated by high profile investments in foundational model developers, such as Nvidia's $5 Billion commitment to Safe Superintelligence, a quieter, far more consequential capital allocation unfolded across the enterprise software ecosystem. Within a 72-hour window, major security acquirers and venture capital syndicates deployed over $1.37 Billion across five distinct transactions, all addressing a singular, emerging failure point: the security, identity governance, and runtime control of autonomous AI agents operating within enterprise networks. This cluster of transactions occurred before the market had established a standardised nomenclature for the category. The exits of Oasis Security and Permiso Security to market incumbents, alongside massive private capital injections into Onyx Security, Inforcer, and Cantina, signal an industry-wide realisation that existing Identity and Access Management (IAM) and Data Security Posture Management (DSPM) architectures are structurally incapable of governing autonomous non-human actors. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Strategic Overview of the Late July 2026 Transactions The five transactions executed between July 27th and July 31st, 2026, represent an uncoordinated yet unified bet by corporate acquirers and tier-one venture investors. Buyers and investors operated independently, yet arrived at identical conclusions regarding the urgency of non-human identity (NHI) governance and agentic control planes. Target / Company Acquiring Buyer / Lead Investor Deal Type Deal Valuation / Funding Amount Core Technical Specialisation Source Oasis Security Cyera Acquisition (LOI) $1.0 Billion (~$700M Cash + Stock) Non-Human Identity (NHI) & Agentic Access Governance Various Permiso Security Okta Acquisition ~$200 Million (Mostly Cash) Multi-Cloud Identity Threat Detection & Response (ITDR) Various Onyx Security Bessemer Venture Partners Series B $113 Million ($640M Post-Money Val) Enterprise AI Control Plane & Runtime Agent Monitoring Various Inforcer Undisclosed (Series C Syndicate) Series C $50 Million Microsoft Security & AI Management for MSPs Various Cantina Framework Ventures Stealth Launch / Seed $8 Million ($16.5M Total Raised) Automated Agentic Remediation & Post-Triage Fixes Various Detailed Deconstruction of the Five Capital Allocations Cyera Acquires Oasis Security ($1.0 Billion) Data security platform Cyera executed a letter of intent to acquire Israel-based Oasis Security for approximately $1 Billion, consisting of roughly $700 Million in cash and the remaining balance in Cyera equity. Founded in 2022 by Danny Brickman and Amit Zimerman, veterans of Israel’s elite military intelligence units (Talpiot and Unit 81), Oasis had previously raised $195 Million, including a $120 Million Series B led by Craft Ventures in early 2026. The acquisition represents the first billion-dollar valuation assigned specifically to the non-human identity governance category. Cyera, which raised $600 Million at a $12 Billion valuation in June 2026 and generates over $200 Million in Annual Recurring Revenue (ARR), deployed its balance sheet to bridge data security with machine identity. Oasis provides real-time discovery, context assignment, and lifecycle governance for service accounts, API keys, OAuth tokens, and autonomous AI agents across IaaS, PaaS, SaaS and on-premises infrastructure. Under the integrated architecture, Cyera’s core data classification engine pairs directly with Oasis’s identity governance layer. While Cyera determines the sensitivity and location of enterprise data, Oasis establishes the identity context, permissions, and behavioral parameters of the software entities attempting to reach that data. Merging these capabilities creates a single control system that decides what every human, machine, and autonomous agent can see and execute across the enterprise. Okta Acquires Permiso Security (~$200 Million) Within 48 hours of the Cyera-Oasis agreement, market-dominant enterprise identity vendor Okta announced a definitive agreement to acquire Permiso Security for approximately $200 Million in an all-cash transaction. Permiso, co-founded by former FireEye executives Paul Nguyen and Jason Martin, built an Identity Threat Detection and Response (ITDR) engine that monitors runtime behaviors across multi-cloud environments. The acquisition integrates Permiso's 2,500+ research-driven identity risk signals and its specialized runtime capabilities into Okta’s core platform. Crucially, Okta acquired Permiso’s dynamic "SandyClaw" sandbox. SandyClaw isolates and evaluates AI agent skill sets, Model Context Protocol (MCP) servers, prompts, and external plugins prior to runtime execution, preventing malicious payloads or untrusted supply chain dependencies from compromising the agent's identity context. Onyx Security Raises $113 Million Series B ($640 Million Valuation) Led by Bessemer Venture Partners, with participation from Cyberstarts, TCV, Conviction, FirstMark, Vintage, QuantumLight, and G Squared, Onyx Security closed a $113 Million Series B funding round. The round valued the two-year-old startup at $640 Million, just four months after it emerged from stealth with a fourfold increase in revenue. Co-founded by Maxim Bar Kogan (former Unit 8200 officer) and Gil Elbaz, Onyx operates as a real-time AI control plane. Unlike passive governance tools, Onyx uses proprietary models to evaluate an AI agent's reasoning chain step-by-step. If an agent attempts an unauthorized action, exhibits non-deterministic drift, or experiences prompt injection or memory poisoning, Onyx’s "Guardian Agent" intervenes at runtime to block, correct, or escalate the action. Inforcer Raises $50 Million Series C London-based Inforcer secured $50 Million in Series C financing to scale its automated Microsoft security and AI management platform. Coming 12 months after a $35 Million Series B, Inforcer’s rapid capital expansion targets Managed Service Providers (MSPs). As small- and medium-sized businesses (SMBs) rapidly turn on native AI agents within their Microsoft 365 and Azure environments, they lack in-house security teams to configure governance policies. Inforcer automates the policy enforcement and configuration baseline layer across multi-tenant MSP environments, preventing misconfigured AI agents from inheriting tenant-wide admin rights. Cantina Emerges from Stealth with $8 Million ($16.5 Million Total Raised) Cybersecurity startup Cantina launched from stealth with an $8 Million round led by Framework Ventures, bringing its total capitalisation to $16.5 Million. Founded by security researchers with experience at Coinbase, Mastercard, and UBS, Cantina addresses the post-discovery vulnerability bottleneck. Recognizing that AI capabilities are accelerating vulnerability discovery beyond human patching capacity, Cantina deploys autonomous AI agents to triage, prioritise, generate code fixes and verify remediation steps across complex codebases at machine speed. Structural Drivers: The Proliferation of Non-Human Identities The simultaneous capital deployments in late July 2026 stem from a systemic breakdown in modern network architecture: the ratio of human to non-human entities operating inside enterprise environments has inverted beyond the capacity of legacy identity systems. Historically, enterprise Identity and Access Management (IAM) was architected around human employees authenticating through Single Sign-On (SSO), multi-factor authentication (MFA), and static role-based access control (RBAC). Modern cloud-native adoption, microservices, and autonomous software agents have rendered this human-centric perimeter obsolete. Data from the Cloud Security Alliance (CSA) indicates that non-human identities outnumber human identities by an average ratio of 45:1 across global enterprises. In cloud-native environments, this ratio climbs to 144:1, and in the densest microservice deployment architectures, it exceeds 500:1. Institutional audits demonstrate the scale of this disparity; for example, an audit of a Fortune 500 financial institution logged over 4.2 million non-human identities against a human workforce of 50,000. Furthermore, non-human identities associated with AI agents expanded by nearly 500% within Fortune 500 environments over the six months preceding mid-2026, making them the fastest-growing account category in enterprise computing. Over 28.65 Million hardcoded secrets were exposed in public code repositories in 2025 alone, a 34% single-year increase. Within this set, secrets tied to AI infrastructure, such as API tokens, vector database keys, and LLM service credentials, grew by 81% year-over-year to 1.27 Million exposed credentials. Legacy identity tools assume human interaction patterns characterized by deterministic access paths, predictable working hours, manual approval tickets, and long-lived sessions. AI agents, by contrast, execute thousands of non-deterministic actions per minute, perform dynamic tool integrations, and initiate cross-domain data retrievals, leaving traditional security teams blind to their operation. Metric / Governance Dimension Industry Benchmark / Empirical Data Operational Implication Source CISO NHI Defense Confidence 15% express high confidence 85% of security leaders admit vulnerability to non-human identity exploits. Various Legacy IAM Adequacy for AI 8% express high confidence 92% view existing identity architectures as incapable of governing AI agents. Various Shadow AI & Breach Correlation Shadow AI present in 43% of breaches Ungoverned AI adoption adds over $1M in average incident cost. Various Gartner AI Breach Forecast 25% of enterprise breaches by 2028 One in four security incidents will originate from compromised or rogue agents. Various Macro Venture Capital Shift $8.1B in 2026 YTD vs $324M in 2025 A 25-fold year-over-year surge in agentic AI governance capital allocations. Various Technical Architecture of Agentic Governance and Control Planes Securing an enterprise environment populated by autonomous agents requires shifting from static credential management to dynamic, runtime access control. The technologies acquired or funded during the week of July 27th, 2026, illustrate an emerging five-layer technical stack designed for agentic AI security. The foundational layer consists of Data and Identity Discovery, exemplified by Cyera and Oasis, which establishes real-time visibility over non-human identity sprawl, uncovers hidden secrets, assigns ownership, and correlates credentials with underlying data sensitivity. Operating directly above discovery is Dynamic Provisioning and Least-Agency Brokering, which replaces permanent static service accounts with task-bounded, short-lived tokens and Zero-Standing Privilege (ZSP) frameworks. The third layer introduces Runtime Threat Detection and Sandboxing, pioneered by Permiso and Okta, which isolates agent skill sets, Model Context Protocol (MCP) servers, and external plugins in secure sandboxes to analyse execution paths before deployment. The fourth layer is the Inline Reasoning Control Plane, spearheaded by Onyx Security, which uses proprietary supervisory models to monitor an agent's step-by-step reasoning chain, intervening instantly if prompt injection, memory poisoning, or policy drift occurs. Finally, the stack closes with Automated Remediation, represented by Cantina, which uses autonomous agents to triage, generate verified code patches and resolve security vulnerabilities at machine speed. Architectural Dimension Legacy Identity & Access Management (IAM) Agentic Access Management (AAM) & Runtime Control Source Principal Type Human employees, deterministic service accounts Autonomous AI agents, sub-agents, dynamic workloads Various Authentication Vector Usernames, passwords, hardware MFA, static API keys Ephemeral tokens, cryptographic workload attestation Various Authorization Granularity Static Role-Based Access Control (RBAC) Dynamic Attribute-Based & Reasoning-Aware Control Various Session Lifetime Hours, days, or permanent static credentials Task-bound, ephemeral (expires instantly post-execution) Various Behavioral Expectation Deterministic (predictable, repeatable paths) Non-deterministic (probabilistic model reasoning) Various Inspection Plane Boundary ingress/egress, authentication logs Runtime evaluation of reasoning steps, prompts, MCP tools Various Threat Vectors Phishing, credential stuffing, session hijacking Prompt injection, memory poisoning, sub-agent delegation drift Various Key Technical Mechanisms Zero-Standing Privilege (ZSP) and Ephemeral Credential Brokering Standard service accounts frequently operate with permanent, high-privilege credentials embedded in code or configuration files. Agentic Access Management enforces a Zero-Standing Privilege architecture. When an AI agent is invoked to complete an operational workflow, such as compiling a quarterly financial report, a centralised identity broker issues a temporary, scoped token. This token grants access restricted exclusively to the specific database tables required for that exact task. The moment the task completes, or if a short timeout threshold is reached, the token is automatically revoked across all touched environments, returning the agent's baseline standing privilege to zero. Runtime Reasoning Inspection and Step-Level Enforcement Pioneered by control plane platforms like Onyx Security, runtime inspection introduces inline proxying of LLM inference chains. As an agent plans its execution path, decomposing a high-level goal into sequential API calls, the control plane evaluates each reasoning step against organisational security policies. If an agent experiences a prompt injection attack or operational drift and attempts to exfiltrate customer data to an unapproved external endpoint via Model Context Protocol (MCP), the control plane detects the unauthorised step. A specialised Guardian Agent intercepts the call in real time, blocking the specific exfiltration attempt and correcting the agent's execution path without crashing the surrounding application workflow. Dynamic Tool Chain Sandboxing Okta’s acquisition of Permiso’s SandyClaw sandbox specifically targets the security vulnerabilities inherent in dynamic skill integration. Modern AI agents dynamically load third-party tools, prompt templates, and execution plugins at runtime to fulfill complex user instructions. SandyClaw executes these external inputs inside an isolated sandbox environment prior to runtime integration. By evaluating the tool's underlying code paths, API requests and dependency calls for hidden exfiltration routines or prompt injection payloads, the sandbox verifies the safety of the tool chain before granting the agent access to operational enterprise systems. Strategic Market Dynamics and Emergent Insights The concentration of acquisition capital and venture funding during late July 2026 highlights broader market shifts across the enterprise software and security landscape. The Data-Identity Convergence Paradigm Cyera’s acquisition of Oasis Security demonstrates a shift in cybersecurity market strategy: data security platforms cannot protect sensitive data without controlling the non-human identities accessing it. Historically, Data Security Posture Management (DSPM) operated separately from Identity Governance and Administration (IGA). DSPM identified where sensitive information resided, while IGA managed human access rights. However, in an agentic enterprise, non-human software entities create, duplicate, relocate and transform data autonomously. By integrating Oasis’s agentic identity management into Cyera’s data classification engine, Cyera established a unified control system. This combined architecture evaluates access requests based on real-time data classification, agent intent, and credential risk posture simultaneously. The Attribution Gap and Delegation Chain Risk A major security risk driving capital into non-human identity governance is the Attribution Gap in multi-agent workflows. When a human employee authorises a primary AI agent to execute a task, that primary agent frequently delegates sub-tasks to downstream, specialised sub-agents. For example, an executive assistant agent might task a scheduling agent, a data scraping agent and a financial modelling agent to complete a project. Without agentic identity governance, downstream sub-agents execute API calls using either a shared, highly privileged service account or the inherited identity context of the original human user. If a sub-agent suffers a prompt injection attack or makes an unauthorised data modification, traditional audit logs attribute the action entirely to the human user or the broad service account. This creates an attribution gap that makes post-incident investigation impossible. Governance platforms address this vulnerability by requiring context propagation across the entire delegation chain, ensuring every sub-agent action is cryptographically signed and tied back to both the parent agent and the originating user request. Vulnerability Inflation vs. Agentic Remediation The $8 Million seed funding for Cantina points to a critical operational imbalance: AI models are discovering software vulnerabilities faster than human engineering teams can patch them. Anthropic's "Project Glasswing," utilising advanced Claude models, identified over 1,596 critical vulnerabilities across major operating systems and web browsers, generating 9 zero-day CVEs entirely through automated analysis. Furthermore, Anthropic's designation as a CVE Numbering Authority (CNA) in late July 2026 highlights the industrial scale of AI-driven bug discovery. Conversely, the 2026 Verizon Data Breach Investigations Report revealed that enterprise remediation of known critical vulnerabilities dropped from 38% to 26% year-over-year, driven by human developer burnout and overwhelming alert backlogs. This divergence produces Vulnerability Inflation, where the window between flaw discovery and active exploitation collapses to hours. Because human security teams cannot keep pace with AI-generated discovery volume, defense must also become agentic. Cantina’s model demonstrates that autonomous remediation agents are now required to triage, generate synthetic code patches, and verify fixes at machine speed to close exposure windows before attackers exploit them. Strategic Recommendations for Enterprise Security Leaders The capital movements of late July 2026 demonstrate that securing AI adoption requires immediate changes to enterprise security strategy. Chief Information Security Officers (CISOs) and enterprise architects must transition from human-centric security postures to unified identity and runtime control frameworks. First, organisations must perform an immediate non-human identity audit across all cloud environments, SaaS applications, and on-premises infrastructure. Security teams should deploy automated discovery tools to locate all unrotated service accounts, hardcoded API keys, and unmapped OAuth tokens. Every non-human identity must be mapped to an explicit human sponsor, business owner, and workload context, while removing all orphaned credentials and shadow AI deployments. Second, enterprise identity architectures must deprecate standing privileges for software accounts, shifting entirely to ephemeral, task-scoped access controls. Security teams should enforce Zero-Standing Privilege (ZSP) frameworks supported by dynamic credential brokers. Credentials issued to AI agents must be restricted to the exact resources required for the active task and set to expire automatically upon task completion. Furthermore, explicit human-in-the-loop (HITL) authorization steps must be enforced for high-risk operations, such as wire transfers, bulk data exports, or production infrastructure changes. Third, security architectures must deploy inline runtime control planes and tool chain sandboxing for all generative AI and agentic deployments. Implementing dynamic sandboxing allows organizations to isolate third-party agent skills, prompts, and Model Context Protocol (MCP) integrations, inspecting their execution paths prior to operational integration. Simultaneously, step-level reasoning controls should be deployed to monitor agent inference chains inline, detecting and neutralising prompt injection attempts, memory poisoning, or behavioural drift at runtime. Fourth, enterprise architects must enforce cryptographic delegation chain tracing across all multi-agent framework deployments. Orchestration systems must be configured to pass the originating principal’s identity context through every downstream sub-agent delegation step. Organisations should mandate structured, immutable audit logging that captures the originating user, intermediate sub-agent identities, invoked tools, passed parameters, and execution outcomes, ensuring complete visibility and auditability across complex agentic workflows. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Hugging Face Healthcare Technology: Current Architecture, Enterprise Use Cases and Strategic Roadmap The landscape of artificial intelligence across healthcare and the life sciences is undergoing a structural transformation. Historically constrained by proprietary black-box APIs, prohibitive computational costs, and stringent regulatory requirements regarding patient privacy, healthcare organisations are rapidly re-orienting around open-source, domain-adapted foundation models and local-first execution runtimes. Central to this transition is Hugging Face, which has evolved from a repository for open-source model weights into an enterprise-grade platform powering clinical natural language processing (NLP), multimodal diagnostic imaging, computational drug discovery, and sovereign health data systems. This report presents an analysis of Hugging Face’s healthcare technology ecosystem. It details foundational model architectures, major enterprise and clinical use cases, multi-cloud deployment paradigms, clinical evaluation standards and the strategic technological roadmap shaping the next generation of medical AI. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Domain-Adapted Model Families and Architectures Healthcare applications demand high domain specificity. General-purpose large language models (LLMs) frequently struggle when processing specialised medical nomenclature, dense clinical abbreviations, complex diagnostic logic and multi-modal clinical images. To address these structural limitations, biomedical researchers and enterprise developers host specialised model families on Hugging Face that are engineered specifically for clinical constraints. The OpenMed Local-First Architecture The OpenMed project represents one of the largest open-source clinical NLP initiatives on the Hugging Face Hub, encompassing over 2,200 domain-adapted models licensed under Apache 2.0. Engineered to run on local hardware, ranging from Apple Silicon and mobile devices to multi-GPU server clusters, OpenMed models process clinical text and perform Personally Identifiable Information (PII) de-identification across 34 language codes without transferring patient data over external networks. The core training methodology relies on a dual-stage pipeline combining Domain-Adaptive Pre-training (DAPT) with parameter-efficient Low-Rank Adaptation (LoRA). During DAPT, base encoder backbones process a 350,000-passage mixed corpus (~90 million tokens) derived from PubMed abstracts, arXiv biomedical papers, MIMIC-III clinical records, and ClinicalTrials.gov descriptions. LoRA adapters are injected into the query and value matrices of transformer attention layers with rank r = 16 and scaling factor $\alpha = 32, updating less than 1.5% of total underlying parameters while preserving the representational capability of foundational backbones such as DeBERTa-v3-large, PubMedBERT-large, and BioELECTRA-large. For token classification tasks, a single linear layer maps the final hidden state h_i to class probabilities: P(y_i \mid x_{1:n}) = \text{softmax}(W_{\text{cls}} h_i + b_{\text{cls}}) This streamlined architectural design retains compact adapter weights between 15 MB and 20 MB, enabling sub-millisecond token processing and dynamic model hot-swapping in production environments. Model Variant Parameter Scale Primary Deployment Target Core Functional Focus TinyMed / ElectraMed 33M – 135M Edge Devices, Mobile (iOS/Android), Browser (WebGPU) Real-time clinical entity tagging, on-device mobile PII redaction, low-latency screening. SuperClinical / SuperMedical 125M – 434M Workstations, Standard Laptops, Single GPUs Production workhorse for clinical Named Entity Recognition (NER), disease/drug extraction, EHR ingestion. BigMed / MultiMed / XLarge 560M – 770M Dedicated GPU Clusters, High-Memory Cloud Nodes Maximum-accuracy research pipelines, complex genomic entity parsing, multi-label oncology classification. Google MedGemma and Health AI Foundations Google’s MedGemma family, available on the Hugging Face Hub under the Health AI Developer Foundation terms, adapts Gemma 3 architectures specifically for medical text and image comprehension. MedGemma is distributed across three primary parameter scales: a 4B multimodal model, a 27B text-only model and a 27B multimodal model. The multimodal variants integrate MedSigLIP, a specialised vision encoder pre-trained on diverse, de-identified medical imaging sets covering chest X-rays, histopathology slides, dermatology photos and fundus ophthalmology images. The language components are trained on clinical literature, medical question-answering pairs, and FHIR-structured Electronic Health Records (EHR). Benchmark Task / Dataset Evaluation Metric Gemma 3 4B (Base) MedGemma 4B Gemma 3 27B (Base) MedGemma 27B Multimodal MedGemma 27B Text-Only MIMIC CXR (Top 5 Conditions) Macro F1 81.2 88.9 71.7 90.0 — CheXpert CXR (Top 5 Conditions) Macro F1 32.6 48.1 26.2 49.9 — PathMCQA (Histopathology) Accuracy (%) 37.1 69.8 42.2 71.6 — US-DermMCQA (Dermatology) Accuracy (%) 52.5 71.8 66.9 71.7 — EyePACS (Fundus Retinopathy) Accuracy (%) 14.4 64.9 20.3 75.3 — SLAKE (Radiology VQA) Tokenized F1 40.2 72.3 42.5 70.0 — MedQA (4-Option Clinical Board) Accuracy (%) 50.7 64.4 74.9 85.3 (0-shot) / 87.0 (b-of-5) 87.7 (0-shot) / 89.8 (b-of-5) MedMCQA (Multi-choice Medical) Accuracy (%) 45.4 55.7 62.6 70.2 74.2 AfriMed-QA (Regional Medical QA) Accuracy (%) 48.0 52.0 72.0 72.0 84.0 Complementing MedGemma, Google’s broader Health AI Developer Foundations collection provides targeted domain models. These include MedASR, a lightweight automatic speech recognition model pre-trained for transcribing clinician-patient conversations; TxGemma, optimised for therapeutic target prediction; HeAR, an acoustic model trained to detect respiratory anomalies from lung sound recordings; and Path Foundation, designed for high-resolution patch-level histopathology analysis. Biological Foundation Models and Ecosystem Contributions Beyond language and diagnostic vision, Hugging Face hosts an expanding suite of specialised bio-molecular foundation models. Through initiatives such as Hugging Face for Health (hf4h), developers access protein structure generators and sequence design tools. Key systems include ProteinMPNN for inverse protein folding and sequence design from structural backbones, DiffDock for molecular docking pose prediction, and ESMFold for atomic-level 3D protein structure prediction directly from primary amino acid sequences. Concurrently, global research teams like Shanghai AI Lab’s General Medical AI (GMAI) project deploy general-purpose models targeting multi-organ 2D/3D image segmentation, surgical video comprehension, and multi-agent clinical coordination systems. Major Enterprise Use Cases Across Healthcare and Life Sciences Hugging Face's infrastructure supports four primary enterprise sectors: clinical NLP and data privacy, bio-pharmaceutical R&D, enterprise generative AI platforms, and sovereign public health infrastructure. Initiative / Enterprise Operational Focus Primary Hugging Face Stack Measured Operational Impact OpenMed Local Deployment Local Clinical NLP & HIPAA/GDPR De-identification OpenMed-NER, BioClinicalModern, MLX Backend, ONNX Mobile 3.3× throughput on CPU, 0 KB data egress, coverage across 18 Safe Harbor PII types. SandboxAQ (SAIR) Computational Drug Discovery & Binding Potency Prediction sair.parquet, 5.24M 3D structures, Boltz1 Co-folding, Hugging Face Hub 1,000× speedup over physics simulations, 40% dark proteome structural coverage. Ryght Enterprise Platform Life Sciences Copilots & Multimodal Data Querying Text Generation Inference (TGI), Text Embeddings Inference (TEI), HF Expert Support Document assembly timeline reduced from weeks to hours, zero third-party rate limits. Health Data Hub (PARTAGES) Sovereign French Medical AI & Federated Evaluation Sovereign French LLMs, PARTAGES Synthetic Generation Engines, HF Spaces Automated clinical note processing across 20+ French hospital systems. Clinical NLP and Privacy-Preserving Data Processing Unstructured Electronic Health Record (EHR) text contains critical clinical observations but is heavily regulated under statutes such as HIPAA in the United States and GDPR in the European Union. Using OpenMed models hosted on Hugging Face, clinical institutions deploy zero-trust, local-first redaction workflows. These models identify all 18 HIPAA Safe Harbour identifier categories across 55 distinct PII entity classes. The detection mechanism combines token classification with contextual windowing. A 100-character evaluation window applies scoring rules where explicit keywords (e.g., MRN:, SSN:, DOB:) dynamically elevate the confidence scores of neighbouring numerical or string tokens. Built-in checksum validators evaluate candidate entities against standardised patterns, such as French NIR numbers, Italian Codice Fiscale, Spanish DNI, and standard Luhn credit algorithms, to suppress false positives. Executing these models locally via Apple Silicon’s MLX engine or optimized ONNX Runtime binaries yields a 24× to 33× execution speedup over unoptimised CPU setups while guaranteeing complete network isolation. Bio-Pharmaceutical R&D and Structure-Based Drug Design Traditional wet-lab hit-to-lead optimisation and binding affinity characterisation are costly and time-intensive. The publication of SandboxAQ’s Structurally Augmented IC_{50} Repository (SAIR) on Hugging Face demonstrates how open structural data transforms life sciences R&D. SAIR couples 3D molecular structures directly with empirical binding affinity labels. The dataset encompasses 5.24 Million distinct 3D co-folded protein-ligand complexes generated from 1 Million unique pairs using the Boltz1 co-folding model. The compute execution required over 130,000 GPU hours across a cluster of 760 NVIDIA H100 GPUs on Google Cloud Platform, sustaining >95% compute utilisation. Every 3D structural complex is paired with validated IC_{50} (half-maximal inhibitory concentration) potency labels curated from ChEMBL and BindingDB. Structural validity was verified using PoseBusters, with 97% of generated complexes passing chemical sanity and physical plausibility benchmarks. Crucially, over 40% of target proteins in SAIR lack experimental structural records in the Protein Data Bank (PDB), providing actionable structural hypotheses for previously un-targetable disease mechanisms. By training deep affinity models on SAIR data, bio-pharma teams predict target binding strengths and off-target toxicities in silico, achieving up to a 1,000× speedup over traditional physical simulation models. Enterprise AI Infrastructure Integration Constructing enterprise generative AI platforms for health sciences requires balancing throughput optimisation with strict data privacy mandates. Enterprise platform provider Ryght utilised Hugging Face's infrastructure libraries and Expert Support Program to construct its life sciences platform. Ryght implemented a pluggable LLM architecture utilising Hugging Face's Text Generation Inference (TGI). This design routes requests dynamically to specialised open-source medical models deployed on customer-managed endpoints, eliminating lock-in to commercial API providers. To query unstructured EMR records, laboratory logs and patent databases without encountering API rate limits or latency bottlenecks, Ryght integrated Text Embeddings Inference (TEI). TEI’s dynamic batching and GPU queue management eliminate processing bottlenecks during concurrent multi-user access, accelerating complex multi-source document assembly from weeks to hours. Sovereign Public Health Infrastructure The PARTAGES project, hosted by France's Health Data Hub on Hugging Face Spaces, exemplifies the growth of sovereign health AI frameworks. PARTAGES provides open-source French-language medical language models designed to generate synthetic clinical reports, parse narrative text and automate document anonymisation. A key milestone of the initiative is the deployment of a sovereign federated evaluation platform across 20 national hospital facilities. This architecture allows algorithms to be benchmarked on real-world patient records within a secure, compliant local governance boundary. Enterprise Infrastructure, Cloud Deployment and Security Governance Deploying open-source healthcare AI into enterprise IT systems requires balancing open science accessibility with cloud networking, procurement and security requirements. Major cloud providers have integrated Hugging Face infrastructure directly into their commercial platforms to support compliance-bounded deployment. Enterprise healthcare organisations often operate under approved vendor lists and strict procurement constraints that prevent direct execution of unvetted code repositories. To streamline compliance, Hugging Face models are packaged directly within major cloud marketplaces. On AWS Marketplace, OpenMed provides 45 pre-packaged clinical models, allowing health systems to deploy containerized endpoints onto Amazon SageMaker via single click procurement drawing from existing enterprise cloud budgets. On Google Cloud, a joint engineering partnership provides Hugging Face Deep Learning Containers (DLCs) natively integrated with Vertex AI, Google Kubernetes Engine (GKE), and Cloud Run. A dedicated caching gateway mirrors Hugging Face repositories directly within Google Cloud regions, reducing large model download latencies from hours to minutes. Hardware optimisation libraries such as optimum-tpu enable zero code change compilation across NVIDIA GPUs and Google Cloud TPUs. For gated models, such as MedGemma or custom clinical weights requiring signed data access agreements, Microsoft Azure AI Foundry integrates directly with Hugging Face user access tokens. Azure AI Foundry uses secret injection (HF_TOKEN) to verify that the requesting enterprise tenant possesses authorised permissions from the model publisher on Hugging Face before downloading and deploying the model to isolated online endpoints. Enterprise deployments also demand rigorous artifact security. Models hosted via Vertex AI and Google Cloud Model Garden undergo automated security scans powered by Google's Threat Intelligence platform and Mandiant to verify that weights and container binaries are free from embedded malicious payloads. The necessity of strict sandbox isolation was underscored by recent platform security incidents where automated agent execution exploited vulnerable customer endpoints in third-party environments (such as Modal Labs sandbox setups), emphasising the critical need for isolated container boundaries when running unvetted model code. Clinical Rigour, Evaluation Standards and Model Vulnerabilities Deploying generative language and vision models into clinical workflows introduces risks regarding diagnostic accuracy and safety. Systematic evaluation research across the Hugging Face community highlights notable vulnerabilities in current models, emphasising the necessity of standardised evaluation protocols. Fragility and Systematic Biases in Clinical LLMs Evaluations of state of the art models reveal significant sensitivity to minor phrasing changes and underlying dataset biases: Brand vs. Generic Drug Name Fragility (The RABBITS Study): Swapping a commercial brand name for its generic chemical equivalent (e.g., replacing Advil with ibuprofen) causes an average performance drop of 4% on medical knowledge benchmarks like MedQA and MedMCQA. This degradation stems from dataset contamination, where pre-training corpora overfit to specific commercial terms rather than mastering underlying pharmacological concepts. Commercial Association Biases in Oncology: In complex clinical reasoning tasks, models regularly demonstrate positive association bias toward brand-name oncology drugs, associating them with superior efficacy, while linking identical generic equivalents with adverse side effects, despite chemical identity. Demographic Representation Misalignments (The Cross-Care Study): Evaluations of prominent pre-training suites (such as Pythia and The Pile) show that LLM diagnostic outputs misalign with real-world epidemiological disease prevalence across racial, ethnic, and gender groups. These representation biases persist across non-English translations, leading to disparate diagnostic recommendations. Susceptibility to Clinical Misinformation (The PERSIST Study): When prompted with flawed clinical premises (e.g., asking the model to draft a clinical note advising patients against a generic drug because its brand counterpart reported new side effects), state-of-the-art LLMs routinely comply. Although the models can verify chemical equivalence when queried directly, they fail to challenge illogical clinical premises unless explicitly instructed to evaluate logical consistency prior to generating responses. Standardised Reporting: The TRIPOD-LLM Framework To address these evaluation challenges, clinical AI researchers established the TRIPOD-LLM Statement (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis - LLM). Published as a living standard on Hugging Face, TRIPOD-LLM provides a 19-item main checklist expanded across 50 detailed sub-items. The framework mandates precise reporting of pre-training data cutoffs, demographic distribution profiles, human oversight protocols, and boundaries of autonomous operational deployment. Strategic Technological Roadmap and Future Directions The technological roadmap for open-source healthcare AI hosted on Hugging Face reflects a transition from static entity recognition toward reasoning-capable clinical systems. Near-Term Development Targets Development priorities across open-source healthcare projects target immediate operational limitations in clinical NLP: Assertion Status and Temporal Qualification: Next-generation clinical tokenizers are incorporating assertion classifiers to qualify extracted medical entities. These systems determine whether a condition is present, absent(negated), hypothetical, or historical, attaching temporal parameters (e.g., acute presentation vs. past surgical history) to prevent misclassifications in automated billing and diagnostic coding. Clinical Decoder Models: Open-source development is expanding beyond traditional encoder models (such as BERT variants) toward medium-scale decoder architectures ranging from 500M to over 120B parameters. Fine-tuned on specialised clinical instruction sets, these decoders target automated EHR note summarisation, clinical trial matching, and prior-authorisation appeal drafting. Multilingual PII Expansion: Privacy-preserving de-identification pipelines are expanding to support 34 model-backed languages, integrating localised checksum validation algorithms for global health data compliance. Long-Term Strategic Vision The long-term development trajectory focuses on deeply integrating open-source models into clinical workflows and biological computing platforms: Automated Medical Concept Mapping: Future clinical pipelines will integrate real-time entity grounding to map extracted unstructured terms directly to canonical medical vocabularies, including UMLS, ICD-10/ICD-11 and CPT coding frameworks. Native FHIR Interoperability and Agentic Systems: Autonomous multi-agent frameworks (such as the OpenMed Agent initiative) are being developed to consume and output native Fast Healthcare Interoperability Resources (FHIR) JSON bundles. These systems aim to automate administrative interactions, including prior-authorisation verification and care coordination, supported by auditable execution logs. Ubiquitous On-Device Diagnostics: Leveraging browser runtimes (Transformers.js with WebGPU) and mobile neural backends (Apple MLX and ONNX Mobile), multimodal clinical decision support tools will execute entirely on clinician devices. This local execution paradigm offers sub-second diagnostic processing in air-gapped or low-connectivity environments while maintaining absolute data privacy. Strategic Conclusions Hugging Face has established itself as foundational infrastructure for open-source innovation across healthcare and the life sciences. By providing the platform for localised clinical NLP tools like OpenMed, high-capacity vision-language models like Google's MedGemma, and structural biology datasets like SandboxAQ's SAIR, the platform bridges fundamental computational research and enterprise deployment. For healthcare organisations, life sciences enterprises and technology developers, three strategic imperatives emerge: Prioritising Privacy-Preserving Architecture: On-device and local-first execution runtimes successfully resolve historical data privacy friction, allowing health systems to process sensitive patient data locally without relying on external cloud APIs. Capitalising on Open Structural Datasets: The release of large-scale 3D structural repositories paired with empirical potency metrics accelerates in silico bio-pharma research, dramatically reducing hit-to-lead development timelines. Mandating Rigorous Evaluation: Deploying generative systems into clinical settings requires adopting comprehensive reporting standards like TRIPOD-LLM, actively testing for drug name fragility, and isolating execution environments to ensure safe operating outcomes. As multi-modal foundation models mature and specialised hardware accelerators expand, the open-source ecosystem hosted on Hugging Face will remain central to delivering secure, performant, and equitable AI solutions across global health systems. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Multi-Modal Data, Multi-Omic Profiling and Multi-Model Architectures: The Future of Healthcare Technology Theoretical Foundations and Architectural Evolution of Healthcare AI The landscape of biomedical research and clinical practice is undergoing a structural transition from isolated diagnostic paradigms to unified analytical frameworks. Historically, clinical evaluation relied on compartmentalised observations: radiologists interpreted morphological imaging, pathologists examined histological tissue slices, geneticists analysed targeted DNA sequences and primary care physicians reviewed narrative electronic health records (EHRs). While unimodal machine learning models achieved localised success within these specific domains, they fundamentally failed to capture the non-linear, cross-systemic interactions that characterise complex human pathologies. The emergence of multimodal artificial intelligence addresses this limitation by synthesising heterogeneous data streams, encompassing genomic variants, transcriptomic profiles, proteomic abundances, metabolomic signatures, dynamic medical imaging, longitudinal EHRs and continuous sensor telemetry, into a singular predictive substrate. Integrating complementary clinical data modalities yields systemic diagnostic advantages. Across scoping reviews of deep learning deployments in medicine, multimodal architectures consistently outperform their unimodal counterparts, achieving an average performance gain of 6.2 percentage points in the Area Under the Receiver Operating Characteristic Curve (AUC). The methodological evolution of multimodal data fusion strategies can be delineated across three core architectural paradigms: Concatenation-Based Integration (Early Fusion): Raw or preprocessed feature vectors from distinct modalities are stacked prior to model ingestion. While computationally straightforward, early fusion often suffers from high feature dimensionality, data sparsity, and the risk of subtle biological signals being masked by dominant high-volume modalities. Predictive Aggregation (Late Fusion): Modality-specific models are trained independently, and their intermediate representations or output probability distributions are combined using meta-classifiers or decision rules. Although late fusion isolates modality-specific noise and accommodates asynchronously collected data across hospital departments, it inherently fails to model early cross-modal feature interactions. Transformation-Based and Graph-Based Integration (Intermediate/Parallel Fusion): Advanced architectures project heterogeneous data types into a shared latent space or unified topological graph, allowing neural networks to model intra-modality and inter-modality dependencies simultaneously. Models employing graph convolutional networks (GCNs) and self-attention mechanisms operate at this layer, establishing feature-level biological interactions that exist independently of patient sample distribution. This architectural progression is further augmented by the transition from task-specific models to broad multi-model ecosystems and Generalist Medical AI (GMAI) architectures. Pre-trained via self-supervision on massive, multi-institutional datasets, GMAI models leverage in-context learning to execute diverse clinical tasks, ranging from zero-shot disease risk stratification to multi-modality diagnostic reasoning, without requiring custom task-specific parameters or fine-tuning. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Single Cell Resolution and Multi-Omic Integration Frameworks To comprehend the molecular mechanisms of complex pathologies such as cancer, neurodegeneration, and autoimmune dysfunction, machine learning systems must process biological phenomena across multiple biological strata. Mono-omics analysis provides a partial view of cellular regulation; single-cell multi-omics integration is required to reconstruct the complete cascade of information transfer from genome to epigenome, transcriptome, and proteome. High-throughput single-cell assays simultaneously capture distinct cellular layers, generating multi-dimensional datasets that resolve tissue heterogeneity and trace cellular differentiation trajectories. Modality / Method Primary Biological Layers Measured Technical Mechanism Key Analytical Output G&T-seq Genomic DNA & mRNA Transcriptome Physical separation of poly-A tail mRNA from genomic DNA within single cells prior to parallel sequencing. Identifies cell-specific genomic copy number variations (CNVs) and direct transcriptomic consequences. DR-seq Genomic DNA & mRNA Transcriptome Quenched gDNA and mRNA amplification protocols without physical cell separation. Maps intra-tissue genetic heterogeneity directly to functional cellular gene expression profiles. CITE-seq Surface Proteome & mRNA Transcriptome Oligonucleotide-barcoded antibody conjugation targeting cell-surface epitopes combined with single-cell RNA-seq. Resolves surface protein expression alongside full transcriptomic profiles, overcoming post-transcriptional disconnects. REAP-seq Cell-Surface Proteins & mRNA Transcriptome Uses antibody-conjugated small polymer tags paired with high-throughput microfluidic single-cell sequencing. Measures protein abundance and RNA expression levels in parallel to elucidate post-transcriptional regulatory mechanisms. TEA-seq Targeted Epitranscriptome & Transcriptome Targeted enzymatic amplification of specific RNA modifications combined with single-cell sequencing modalities. Elucidates localized epitranscriptomic modifications and their precise regulatory influence on mRNA transcription dynamics. ASAP-seq Nascent mRNA & Transcription Rates Rapid quantification of newly synthesized single-stranded adenine-rich transcript populations. Quantifies real-time transcriptional bursts and kinetics at individual cellular resolution. Integrating these omics streams requires neural architectures capable of navigating extreme data imbalance, feature redundancy and complex non-linear interactions. Supervised classification and subtyping frameworks have advanced beyond basic dimensionality reduction. Cancer Integration via Multi-kernel Learning (CIMLR) combines kernel-based learning algorithms to integrate genomic, epigenomic and transcriptomic matrices, enabling accurate survival rate prediction and molecular subtype segregation. Similarly, the Multi-Omics Graph Convolutional Network (MOGONET) utilises omics-specific GCNs to learn intra-omics feature representations independently, projecting these embeddings into a View-Correlation Discovery Network (VCDN) to uncover cross-omics label correlations. Other models like MoGCN apply autoencoders for early fusion before projecting merged representations into a sample-similarity GCN, while SUPREME trains isolated GCNs on modality-specific patient networks before integrating latent embeddings to mitigate noise transfer. Addressing a core limitation of sample-similarity GCNs, their inability to capture direct feature-to-feature molecular interactions, the SynOmics framework operates directly in feature space. SynOmics constructs intra-omics feature graphs alongside cross-omics bipartite networks, deploying a parallel learning architecture that simultaneously models within-modality and across-modality feature dependencies at every neural layer. Complementing omics integration frameworks, specialised foundational models pre-trained on vast genomic sequences treat nucleotide sequences as complex languages, learning regulatory codes, non-coding variant impacts and chromatin accessibility directly from raw DNA and RNA. Model Name Parameter Scale Architecture Base Training Data Corpus Core Capability / Application DNABERT 86M – 89M Transformer Encoder Human Reference Genome K-mer tokenization for gene promoter identification and transcription factor binding prediction. DNABERT2 117M Efficient Transformer 135 Species Genomes Multi-species cross-genomic contextual embedding and variant effect prediction. Enformer 23M CNN + Transformer Human and Mouse Genomes Long-range genomic sequence processing for gene expression and chromatin state prediction. HyenaDNA Variable (1k–1M context) Hyena Long Conv Operator Human Reference Genome Sub-quadratic processing of ultra-long genomic sequences up to 1 million tokens at single-nucleotide resolution. EpiGePT 71.3M CNN + Transformer Human Genome + Transcription Factors Epigenomic signal prediction and cell-type-specific gene expression modeling. Evo 7B Striped Hyena Operator Prokaryotic, Viral, & Plasmid Genomes Multi-scale biological generation, predicting DNA, RNA, and protein function from molecular sequences. Evo2 1B / 7B / 40B Striped Hyena 2 Operator 128,000 Genomes (Eukarya, Prokarya, Archaea) Pan-genomic representation learning, zero-shot variant evaluation, and synthetic biological design. Multi-Model Systems, Medical Foundation Models and Knowledge Graph Reasoning Combining multi-omic data with spatial medical imaging and unstructured EHR narratives requires multi-model architectures capable of explicit biological reasoning. Geometric deep learning, multimodal vision-language models and mixture-of-experts paradigms represent key developments in this domain. A major application of graph foundation models is zero-shot drug repurposing across large disease networks. The TxGNN architecture demonstrates this approach, addressing the challenge of identifying therapeutic options for diseases with limited molecular understanding or no existing treatments. Pre-trained on a clinical knowledge graph connecting 17,080 recognised diseases and 7,957 therapeutic candidates alongside biological entities such as genes, proteins, pathways and phenotypes, TxGNN formulates drug discovery as a zero-shot link prediction task. The model projects diseases, drugs, and biological targets into a low-dimensional latent space that preserves the topological geometry of the knowledge graph. To infer candidates for diseases lacking established treatments, TxGNN deploys a metric learning module that calculates relational similarity across disease neighborhoods. This enables the model to transfer mechanistic therapeutic rationales from well-characterized, treatable conditions to novel or neglected disease profiles without requiring parameter updates or fine-tuning. Under zero-shot benchmark evaluations, TxGNN achieves a 49.2% improvement in indication prediction accuracy and a 35.1% improvement in contraindication identification over baseline algorithms. Real-world validation demonstrates that TxGNN's zero-shot therapeutic rankings align with off-label prescribing patterns observed across healthcare systems. To enable clinical adoption, TxGNN incorporates an explainer module that extracts multi-hop paths through the knowledge graph, providing clinicians with interpretable rationales grounded in biological mechanisms. Beyond graph neural networks, multimodal foundation models extend natural language architectures to interpret medical vision and multi-omic data. Model Framework Primary Modalities Underlying Base Models Architectural & Training Characteristics LLaVA-Med Clinical Language, Medical Vision (X-ray, MRI, CT, Histology, Pathology) LLaVA, Vicuna/LLaMA, CLIP ViT Fine-tuned on biomedical visual-instruction datasets; links radiological and histological features with conversational diagnostic reasoning. MedVInT Language, Radiologic & Pathologic Imaging PMC-CLIP, PMC-LLaMA Integrates specialized biomedical visual encoders with domain-adapted LLMs to execute visual question answering and diagnostic synthesis. MedSAM Multi-Modal Medical Image Segmentation Segment Anything Model (SAM) core Trained on 1.57 million image-mask pairs across 10 imaging modalities and over 30 cancer types; provides zero-shot anatomical and lesion segmentation. COMPASS Spatial Transcriptomics, Tumor Microenvironments, Text Pan-Cancer Graph Foundation Model Predicts patient-specific immune checkpoint inhibitor responses by integrating single-cell spatial microenvironments with tumor genomic profiles. ATHENA Clinical Records, Pharmacological Databases, Text Reinforcement Learning Agent + Tool API Network Executes multi-step treatment reasoning across FDA-approved therapeutics by querying 212 specialized biomedical databases. Valuations of multimodal foundation models (e.g., GPT-4V, GPT-5, o3, MedGemma) reveal a strong dependency on textual prompt context during diagnostic image interpretation. When presented with visual diagnostic tasks containing minimal clinical text, vision-language models frequently display degraded performance. However, when provided with expanded clinical text contexts, their diagnostic accuracy increases substantially; for example, model accuracy on specific visual tasks rises from 70% on low-text prompts to 90% on high-text prompts. This contrast indicates that current multimodal models excel at contextual information synthesis rather than isolated visual pattern recognition. To operationalise these large-scale systems, specific deep learning components are dynamically combined: Convolutional Neural Networks (CNNs): Architectures such as VGG19 serve as standard feature extractors for medical radiomics and spatial histopathology. Recurrent Neural Networks (RNNs): Retain contextual memory across sequential time steps, making them suited for processing dynamic, longitudinal EHR streams, wearable biosensor telemetry and dynamic transcriptomic shifts. Mixture of Experts (MoE): MoE architectures address the computational load of processing multimodal inputs by replacing dense neural layers with specialised sub-networks ("experts") managed by dynamic routing mechanisms. In healthcare applications, distinct experts specialise in processing specific data streams, such as dynamic electrophysiological signals, spatial transcriptomics, or unstructured clinical text, scaling total parameter capacity while managing inference costs. Enterprise Infrastructure, Federated Frameworks and National Deployments Translating multimodal, multi-omic, multi-model AI into operational clinical environments requires scalable data management architectures, federated integration systems and dynamic regulatory governance. Traditional relational database management systems struggle with the high dimensionality and scale of biomedical datasets. Modern multimodal infrastructure increasingly relies on data platforms optimised for multi-dimensional arrays and high-throughput ingestion. For example, platforms built on multi-dimensional array structures (such as TileDB) store complex datasets, including population-scale whole genome sequences, spatial transcriptomics, single-cell matrices, and volumetric medical imaging, as uniform multi-dimensional arrays. This array-based representation facilitates parallel querying, reduces data redundancy, and accelerates data loading into deep learning frameworks. Similarly, specialised medical imaging platforms (such as Flywheel) automate the ingestion, de-identification and annotation of complex radiologic and pathologic imaging data, maintaining compliance with regulations such as HIPAA, GDPR, and 21 CFR Part 11 across clinical research networks. At a health-system scale, the implementation of the National Health Service (NHS) Federated Data Platform (FDP) in the United Kingdom illustrates how multimodal data can be connected across nationwide healthcare networks. Rather than constructing a centralised national database, an approach that faced challenges in historical initiatives due to privacy and governance concerns, the FDP utilises a federated deployment model. Under this federated architecture, patient data remains in situ within individual NHS Acute Trusts, Mental Health Trusts and Integrated Care Boards (ICBs), with each organisation maintaining administrative control over its local platform instance. Cross-organisational analytical query capabilities are achieved through a shared data ontology, enabling near-real-time data access without central physical duplication of patient records. The platform targets core operational areas: elective care recovery, vaccination management, care coordination (such as utilising the OPTICA module for safe discharge planning), supply chain optimisation, and population health risk stratification. The FDP provides the operational backbone to link clinical EHR records with Genomics England, supporting routine whole genome sequencing (WGS) for paediatric rare diseases and oncology, while interfacing with the national NHS Genomic AI Network. As multimodal AI models transition from static algorithms to continuously adaptive systems, regulatory oversight frameworks must adapt accordingly. The United States Food and Drug Administration (FDA) has introduced Predetermined Change Control Plans (PCCP) to govern artificial intelligence and machine learning-enabled medical devices. Under a PCCP framework, device manufacturers outline planned post-market algorithmic modifications, such as iterative retraining on updated multi-omic or demographic datasets, alongside specific protocol validation methodologies to prevent algorithmic drift or bias. This regulatory mechanism allows adaptive multimodal models to update continuously within pre-approved safety boundaries without requiring a new premarket notification or approval for every iteration. Technical Challenges, Structural Limitations and Clinical Translation Despite technical progress, deploying multi-modal, multi-omic, multi-model AI systems in clinical environments introduces operational challenges. Clinical data generation is sparse, asynchronous, and heterogeneous. Diagnostic workups vary widely across individual patients; a patient record may contain high-resolution MRI scans and EHR narratives but lack single-cell transcriptomics or genomic sequencing data. Multimodal architectures must incorporate missing-modality imputation techniques or masked autoencoders to maintain consistent predictions when specific input streams are absent. Furthermore, federated data environments remain vulnerable to upstream data quality issues. Errors, missing fields, or non-standardised clinical terms in primary Electronic Patient Records (EPRs) propagate directly into integrated AI models, making data cleaning and standardisation at the EPR interface essential prior to analytical platform ingestion. Integrating multi-omic and clinical datasets also introduces risks related to latent confounding variables. Deep neural networks can identify subtle statistical correlations, but they may inadvertently base predictions on clinically irrelevant factors. Robustness audits of clinical machine learning pipelines highlight this risk. For example, in computational pipelines designed to score therapeutic candidates for cell replacement or beta-cell reprogramming, models integrating biological and clinical features can become heavily confounded by patient age. Systematic evaluation reveals that such pipelines may assign substantially higher candidacy scores to older patient tertiles (e.g., mean scores of 0.356 in the youngest tertile versus 0.693 in the oldest tertile) due to underlying age-correlated clinical variables rather than target cell biology. Ablation studies further indicate that introducing synthetic transcriptomic features does not automatically yield improvements in predictive AUC over classical, well-balanced models like class-weighted logistic regression. Machine learning models operating on complex tabular or omic datasets must undergo pre-submission robustness audits, bootstrap confidence interval validation, failure case characterisation and counterfactual testing to prevent demographic bias. Translating multi-omic and AI insights into frontline primary care introduces operational workflow challenges. General practitioners often operate within brief consultation windows (such as 10-minute appointments), making raw genomic outputs or complex multi-omic risk scores impractical to review directly. Automated Clinical Decision Support (CDS) tools are required to translate complex model outputs into concise clinical recommendations. Additionally, realising the benefits of pharmacogenomics requires workforce up-skilling. Pharmacists at the point of care must be equipped to interpret pharmacogenomic indicators to adjust drug choices and dosing, reducing adverse reactions. Frameworks such as the NHS Pharmacy Genomics Workforce Strategy reflect the systemic training required to integrate multi-omic AI insights into routine community healthcare. Synthesis and Strategic Outlook The convergence of multi-modal data collection, multi-omic profiling and foundational multi-model architectures represents a transition in healthcare technology. Moving beyond isolated diagnostic streams enables integrative disease profiling, accurate risk stratification, and zero-shot therapeutic discovery across complex conditions. Advancing this paradigm requires coordinated progress across technical, structural, and operational dimensions: Architectural developments must emphasize feature-space graph networks and graph foundation models (such as SynOmics and TxGNN) that explicitly represent cross-omic molecular interactions and multi-hop biological pathways. In parallel, foundational model scaling must continue expanding the capacity of biological language models (such as Evo2 and HyenaDNA) and multimodal generalist platforms to process long genomic sequences and complex clinical data streams. Enterprise infrastructure demands the adoption of non-custodial, ontology-driven federated platforms (such as the NHS FDP) supported by high-performance multi-dimensional array storage engines (such as TileDB) to securely connect clinical and multi-omic data across health systems. Finally, successful clinical translation relies on rigorous evaluation protocols to identify algorithmic bias and age confounding, alongside adaptive regulatory mechanisms (such as FDA PCCP guidance) and clinical workforce up-skilling to ensure AI-driven recommendations are safe, interpretable, and seamlessly integrated into patient care workflows. Through these aligned advancements, healthcare technology shifts from reactive, population-average approaches to a proactive, precise, and systemically integrated model of medicine. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Unifying Digital Care: Analysis of Hinge Health’s $105 Million Acquisition of Cylinder Health The digital healthcare market is undergoing a structural transition as self-insured employers and commercial health plans move away from fragmented, single-condition point solutions toward unified, multi-condition enterprise platforms. A milestone in this market consolidation occurred on August 4th, 2026, when Hinge Health, Inc. (NYSE: HNGE) announced a definitive agreement to acquire Cylinder Health, Inc. (formerly Vivante Health) for $105 Million in cash consideration. Scheduled to close in the third quarter of 2026, this transaction marks Hinge Health’s entry into virtual-first gastrointestinal (GI) care, extending its core leadership in digital musculoskeletal (MSK) therapy and expanding its multi-condition care architecture alongside its Migraine Care Program. This strategic expansion is supported by Hinge Health’s second-quarter 2026 financial performance, characterized by a 53% year-over-year revenue increase to $212.8 million and quarterly free cash flow generation of $99.6 million. Supported by $475.6 million in total cash and liquid assets, Hinge Health is executing an all-cash transaction that broadens its addressable market while avoiding share dilution. The transaction addresses enterprise demand for vendor consolidation, driven by shared biological mechanisms across chronic MSK, neurological, and GI disorders. Under the long-term integration strategy, Hinge Health is combining its core Musculoskeletal platform, its Migraine Care Program and the newly acquired Gastrointestinal Care module onto a unified AI-powered care engine. This multi-condition architecture is scheduled for commercial availability within a single-app interface in 2027, consolidating clinical workflows, intake triage and digital diagnostic capabilities for enterprise clients. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Target Asset Analysis: Cylinder Health’s Market Position and Clinical Capabilities Founded as Vivante Health before rebranding to Cylinder Health in June 2024, the target entity established a specialized virtual care model for digestive wellness and chronic GI disease management. Prior to the acquisition, Cylinder raised approximately $47 Million in total venture capital funding from healthcare investors including 7wireVentures, Health Catalyst Capital, Mercato Partners, Intermountain Ventures, Distributed Ventures, Human Capital, and SemperVirens. The $105 Million purchase price yields an exit valuation exceeding two times total venture capital invested, reflecting the target's enterprise traction and documented clinical outcomes. Cylinder’s commercial footprint spans nearly 100 enterprise clients covering approximately two million lives, with over 150,000 individuals treated across all 50 U.S. states. The company established distribution channels across self-insured employer benefit ecosystems, securing strategic partnerships with two of the three largest pharmacy benefit managers (PBMs) and three of the top five commercial health plans ranked by self-insured market share. Major enterprise clients include the Texas A&M University System, US Foods, and Metro Nashville Public Schools, alongside distribution inclusion within the Alight partner network. Cylinder's flagship offering, the GIThrive platform, provides individualised care across the full acuity spectrum of digestive disorders. Its clinical scope encompasses high-prevalence functional bowel disorders such as Irritable Bowel Syndrome (IBS), Gastroesophageal Reflux Disease (GERD), chronic constipation, bloating, Small Intestinal Bacterial Overgrowth (SIBO), and Celiac Disease, as well as high-cost autoimmune conditions including Inflammatory Bowel Disease (IBD), Crohn’s Disease, and Ulcerative Colitis. The platform integrates a multidisciplinary care team consisting of board-certified gastroenterologists, general practitioners, registered dieticians and certified health coaches. Care delivery is supported by proprietary digital diagnostics and monitoring technologies, including: Computer Vision Stool Scan: An AI-powered feature launched in early 2026 to standardise objective monitoring of stool morphology and bowel patterns. GIMate Biometric Monitor: A handheld breath-analysis device measuring hydrogen levels to track digestive function and food intolerances in real time. Microbiome and Biomarker Testing: Custom gut microbiome analysis paired with dynamic nutritional and lifestyle interventions. Digital Therapeutics: Cognitive Behavioural Therapy (CBT) modules and targeted gut-brain behavioural protocols designed to mitigate stress-induced GI flares. Peer-reviewed clinical validation indicates that 91% of Cylinder members report measurable improvement in GI symptoms, while 92% report enhancements in overall quality of life. For enterprise sponsors, Cylinder achieves a 13% employee engagement rate and delivers up to a 5:1 return on investment (ROI) by driving an 18% reduction in total healthcare spend relative to control groups through reduced emergency department visits, specialised drug optimisation and lower workplace absenteeism. Financial Mechanics, Valuation and Capital Allocation Hinge Health’s acquisition of Cylinder Health is executed from a position of balance sheet liquidity, operational scale, and post-IPO financial performance. Having completed its initial public offering on the New York Stock Exchange under the ticker HNGE on May 22nd, 2025, raising $437.3 Million at a $2.5 Billion market valuation, Hinge Health has translated its commercial momentum into sustained cash flow. For the second quarter ended June 30th, 2026, Hinge Health reported total revenue of $212.8 Million, representing a 53% year-over-year increase from $139.1 Million in Q2 2025. The company expanded its Non-GAAP operating margin from 19% in the prior-year period to 29% in Q2 2026, driven by member conversion rates and automated care processes. Operating cash flow reached $101.4 Million, while quarterly free cash flow rose nearly threefold to $99.6 Million. Financial Metric Q2 2025 Q2 2026 Year-over-Year Growth / Change Total Revenue $139.1 Million $212.8 Million +53.0% GAAP Gross Margin 70.0% 86.0% +1,600 bps Non-GAAP Gross Margin 83.0% 87.0% +400 bps GAAP Operating Income (Loss) $(580.7) Million* $40.4 Million Reversal to Profitability Non-GAAP Operating Income $26.1 Million $61.5 Million +135.6% Non-GAAP Operating Margin 19.0% 29.0% +1,000 bps Net Cash Provided by Operations $20.2 Million $101.4 Million +402.0% Free Cash Flow $32.6 Million $99.6 Million +205.5% GAAP Diluted EPS $(13.10) $0.52 Reversal to Profitability Non-GAAP Diluted EPS $0.30 $0.59 +96.7% Total Enterprise Clients 2,359 2,929 +24.2% LTM Calculated Billings $568.4 Million $861.8 Million +51.6% *Note: Q2 2025 GAAP operating losses were impacted by $591.0 million in stock-based compensation charges recognised in conjunction with the company's May 2025 IPO. As of June 30th, 2026, Hinge Health held $475.6 Million in cash, cash equivalents, marketable securities, and restricted cash. Because the $105 Million purchase price for Cylinder Health is structured as an all-cash transaction, the acquisition is fully funded out of liquid reserves without requiring debt financing or stock issuance. The company's cash flow profile allowed its Board of Directors to concurrently approve a $300 Million expansion to its Class A common stock repurchase program on July 29, 2026. This expansion brought the total aggregate buyback authorisation to $496.5 Million, following the execution of $196.5 Million in stock repurchases under the initial $250 Million program authorised in November 2025. The capability to execute an strategic acquisition while committing $300 Million to share repurchases highlights Hinge Health's financial flexibility. Period / Guidance Horizon Revenue Target Non-GAAP Operating Income Strategic Outlook / Highlights Q3 2026 Guidance $223M – $225M $61M – $63M ~45% YoY revenue growth; 28% Non-GAAP operating margin at midpoint. FY 2026 Full-Year Guidance $856M – $860M $236M – $244M Raised from prior $818M–$824M range; midpoint ($858M) reflects 46% YoY growth. 2027 Integration Horizon Unrated (Growth Catalyst) Margin Accretive Full platform launch of integrated single-app GI Care Program alongside MSK and Migraine. Industry Context, Vendor Consolidation and Commercial Synergies The expansion of Hinge Health into gastrointestinal care addresses challenges in healthcare delivery and employer benefit management. Digestive health conditions represent a major underserved clinical category in the United States, with chronic GI symptoms affecting between 25% and 40% of the U.S. adult population daily. Gastrointestinal disorders account for approximately $135 Billion in direct annual U.S. medical spending, positioning digestive health among the top healthcare cost drivers for self-insured employers. Access is further restricted by geographic specialist shortages, as 69% of U.S. counties lack a practicing gastroenterologist. Consequently, patients frequently cycle through primary care clinics and emergency departments without receiving targeted treatment plans. Over the past decade, self-insured employers added single-condition point solutions to manage specific health areas, such as musculoskeletal pain, diabetes, mental health and digestive care. However, managing multiple vendor contracts, fragmented data systems and separate member applications created administrative burden and low member engagement. Attribute Legacy Point-Solution Architecture Unified Multi-Condition Platform (Hinge Health Strategy) Contracting Structure Multiple disparate contracts across distinct specialty vendors. Single master service agreement covering MSK, Migraine, and GI. User Experience Fragmented member care across separate applications and login credentials. Integrated single-app interface uniting physical, neurological, and GI care. Data Integration Isolated health data silos with limited cross-specialty clinical insights. Unified AI data platform sharing clinical markers across care teams. Distribution Efficiency High customer acquisition costs and duplicate administrative overhead. Cross-selling into existing enterprise account base (~2,929 clients). Hinge Health’s acquisition of Cylinder directly addresses this structural shift. By integrating Cylinder’s digestive health platform into Hinge Health’s enterprise distribution network, which encompasses 2,929 clients, including 42% of the Fortune 500 and the major national health plans, Hinge Health transforms its product suite into a multi-condition platform. From a commercial perspective, this transaction creates cross-selling opportunities. Hinge Health can deploy its enterprise sales force and distribution relationships across PBMs and health plans to cross-sell the GI Care Program into its existing corporate client base. This strategy lowers Cylinder’s historical customer acquisition costs (CAC) while expanding Hinge Health’s Net Dollar Retention (NDR) rate and average contract value (ACV) per covered life. Biological Mechanics and Clinical Synergies Beyond the commercial rationale, combining musculoskeletal, neurological, and gastrointestinal care is supported by established biological mechanisms. Clinical research demonstrates high rates of comorbidity among individuals suffering from chronic joint and spinal pain, pelvic floor dysfunction, migraines, and chronic gastrointestinal disorders. Central sensitization serves as a primary biological bridge connecting these conditions. In patients with chronic musculoskeletal pain and functional GI disorders like Irritable Bowel Syndrome, the central nervous system develops persistent hyper-reactivity, amplifying sensory inputs and pain signals from both somatic structures (muscles and joints) and visceral organs (the digestive tract). Simultaneously, the bi-directional gut-brain axis mediates communication between the central nervous system and the enteric nervous system. Neurological conditions such as migraines frequently co-occur with gastrointestinal dysmotility and dysbiosis due to shared neuro-inflammatory pathways, vascular responses, and serotonin signaling dysregulation. Furthermore, pelvic floor muscle dysfunction links musculoskeletal pelvic pain directly with functional GI pathologies, including chronic constipation, obstructed defecation, and abdominal distress. Treating these co-morbid conditions through a unified virtual platform enables clinicians to address systemic neuro-somatic and visceral dysfunctions co-currently rather than managing isolated symptoms. Hinge Health plans to incorporate Cylinder’s clinical workflows and diagnostic technologies into a unified single-app interface scheduled for commercial launch in 2027. This single-app technology environment will combine multiple proprietary clinical tools: TrueMotion Computer Vision: AI-powered motion tracking that evaluates physical therapy exercises through smartphone camera inputs without physical sensors. Enso Electrical Waveform Hardware: A non-invasive wearable device delivering high-frequency electrical impulse therapy for non-pharmacological pain management. AI Stool Scan and Diagnostic Engine: Computer-vision analysis of stool morphology integrated alongside biometric breath tracking (GIMate) and microbiome sequencing. Unified Algorithmic Triage: AI intake engines that evaluate patient-reported symptoms and direct individuals to cross-trained care teams spanning physical therapists, gastroenterologists, dieticians, and behavioural health coaches. Post-Merger Integration Dynamics, Risks and Competitive Landscape Executing the post-merger integration requires addressing technical, operational, and commercial workflows. Merging Cylinder's patient datasets into Hinge Health's technology platform requires maintaining HIPAA compliance and consolidating data pipelines while preserving HITRUST and SOC 2 security certifications. Operationally, Hinge Health must align Cylinder’s network of gastroenterologists and dieticians with its existing care team of physical therapists, physicians, and health coaches. Clinical protocols must be unified to facilitate cross-specialty coordination and preserve patient care standards. Additionally, consolidating Cylinder's commercial contracts across top-tier PBMs and health plans into Hinge Health’s enterprise master service agreements requires synchronised billing execution to ensure continuous coverage for enterprise clients. From a competitive standpoint, this acquisition alters market positioning across the digital health ecosystem: Standalone GI Point Solutions: Specialised virtual GI startups face competition from an integrated entity backed by Hinge Health’s enterprise client footprint, balance sheet liquidity, and broader clinical scope. Broad Virtual Primary Care Providers: Digital health vendors offering general primary care and chronic disease management programs face a rival with specialised depth across high-cost specialty categories including MSK, Migraine, and GI care. Pure-Play MSK Competitors: Point-solution digital physical therapy providers face increased competitive pressure from Hinge Health’s multi-condition platform, which allows enterprise buyers to address physical, neurological and visceral conditions under a single contract. Conclusions and Strategic Outlook Hinge Health’s $105 Million cash acquisition of Cylinder Health represents a milestone in the digital health sector’s transition toward multi-condition platform consolidation. Utilising its free cash flow ($99.6 Million in Q2 2026) and cash balance ($475.6 Million), Hinge Health is expanding into virtual gastrointestinal care—a $135 Billion medical spend category, without incurring debt or equity dilution. The commercial rationale aligns with enterprise buyer demand for vendor consolidation, replacing single-condition point solutions with an integrated platform capable of treating comorbid chronic conditions. Clinically, the overlapping mechanisms of central sensitisation, gut-brain axis signalling and pelvic floor dysfunction provide a rationale for managing musculoskeletal, neurological and digestive health within a unified care model. As the transaction closes in the third quarter of 2026 and moves toward full platform integration in 2027, Hinge Health is expanding its addressable market and reinforcing its position as a multi-condition digital healthcare platform. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

UK Healthtech M&A Outlook: 20 High Probability Acquisition Targets for Cross Border Strategics Following a prolonged multi-year valuation reset across 2023–2025, the United Kingdom healthcare technology M&A market has entered a highly disciplined, execution-led deal cycle. Driven by structural shifts in healthcare delivery, persistent labour constraints in public health systems, and corporate patent cliffs facing large biopharmaceutical entities, global deal flow is accelerating, with international buyers turning to the UK as a primary incubator for regulatory-cleared, enterprise-grade digital health and TechBio assets. Transaction mechanics have fundamentally detached from the speculative "growth-at-all-costs" framework of the early 2020s. Enterprise valuations are now governed by a paradigm of "Regulatory Darwinism," where valid Medical Device Regulation (MDR/IVDR) certifications, FDA 510(k) clearances and deeply integrated Software-as-a-Medical-Device (SaMD) clinical workflows serve as definitive defensive valuation moats. The convergence of the UK National Health Service (NHS) 10-Year Health Plan, which mandates a structural "Left Shift" of care from acute hospital settings into community and home environments, alongside the Medicines and Healthcare products Regulatory Agency (MHRA) SaMD framework, has de-risked specific high-growth verticals. While domestic private equity platforms continue to consolidate fragmented UK B2B Healthcare IT platforms focused on administrative back-office operations through buy and build strategies, assets specialising in AI-driven drug discovery, medical imaging analytics, remote patient monitoring (RPM), ambient clinical intelligence and specialised women's health are experiencing intense cross-border pull from US and European strategic buyers. US biopharma, global MedTech conglomerates and European healthcare platforms are actively deploying private capital to acquire de-risked UK technologies that offer immediate cross-border commercial scalability and proven clinical utility. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Macro M&A Drivers and Cross-Border Valuation Dynamics Cross-border M&A in the UK healthtech landscape is accelerated by distinct economic, regulatory and technological vectors across both buy-side and sell-side market participants. Mid-market UK healthtech transactions consistently clear in the 4.0x to 6.0x Enterprise Value (EV) / Revenue range for established SaaS and workflow assets, with valuation upside concentrating in assets displaying high capital efficiency and defensible intellectual property. Healthtech Sub-Sector EV / Revenue Multiple Primary Valuation & M&A Drivers AI-First Drug Discovery (TechBio) 8.0x – 15.0x Upfront cash plus milestone bio-bucks; patent cliff mitigation for biopharma. AI Medical Imaging & Regulated SaMD 5.0x – 9.0x FDA clearances/CE marks; prospective radiology workflow efficiency gains. Remote Patient Monitoring & Virtual Wards 4.0x – 8.0x Active patient scale (>100k lives); verified reduction in nurse staffing ratios. Operational Healthcare IT & Workflow Automation 3.0x – 6.0x NHS DTAC compliance; ARR per FTE growth; margin visibility over growth optics. The European "Series B gap" remains a key structural catalyst driving strategic sell-side activity. While early-stage seed and Series A funding rounds remain accessible, late-stage venture capital and private equity investors demand clear evidence of clinical efficacy, established reimbursement pathways, and predictable paths to EBITDA profitability before committing growth capital. With the average timeline to close a Series B round approaching 30 months, venture-backed scale-ups are increasingly pursuing strategic exits or horizontal "Venture-to-Venture" consolidations to combine commercial teams, eliminate administrative redundancies, and present comprehensive platform architectures to international buyers. Concurrently, acquisition strategies among major US and European medical device and biopharma corporations (e.g., Roche, Siemens Healthineers, Abbott, GE HealthCare) are fundamentally compliance-driven. With regulatory compliance eating up to 75% of traditional MedTech development budgets, global corporates view UK assets possessing active FDA 510(k) clearances, Breakthrough Device designations, or EU MDR certifications as premium targets that bypass multi-year regulatory bottlenecks and secure immediate clinical data sovereignty. Target Matrix: Top 20 UK Healthtech Acquisition Candidates The following structured matrix outlines 20 premier UK healthtech scale-ups identified as high-probability acquisition targets for cross-border strategic buyers over the coming 12 months. Target Company Sub-Sector / Vertical Total Capital / Valuation Strategic Acquirer Archetypes Primary Strategic Asset & M&A Catalyst CMR Surgical Surgical Robotics & SaMD $1.2B Raised / ~$3.0B–$4.0B Medtronic, Stryker, Johnson & Johnson Versius modular robotic platform; dual-track exit process; US expansion. Ultromics AI Cardiology Imaging ~$100M Raised (£41M Series C) GE HealthCare, Siemens Healthineers, Philips EchoGo platform; FDA Breakthrough status; Pfizer amyloidosis deal. CHARM Therapeutics AI Drug Discovery (TechBio) $130M Raised ($80M Series B) Bristol Myers Squibb, Eli Lilly, Novartis DragonFold 3D deep-learning engine; CHM-029 menin inhibitor asset. Accurx Primary Care Communications ~$50M Raised (Series B) Epic Systems, Oracle Health, Teladoc, Dedalus 98% NHS GP practice adoption; Accurx Scribe AI workflow deployment. Doccla Virtual Wards & Remote Monitoring $45.9M Series B Philips Healthcare, Baxter, Humana, Best Buy Leading NHS virtual ward provider; rapid European expansion execution. Huma Hospital-at-Home Platform >$300M Raised (Series D) Roche, Abbott, Siemens Healthineers, Elevance Aggregator platform (eConsult/Aluna); national care delivery contracts. Peppy B2B Corporate Health $45M Series B Teladoc, Accolade, Hims & Hers, Personify Enterprise market leader in menopause/fertility; US revenue growth. TORTUS Ambient Clinical AI Voice Venture Backed Microsoft/Nuance, Commure, Abridge, 3M HIS First ambient voice tool to achieve Class IIa SaMD certification. Hertility Health Diagnostic FemTech £4.2M+ Seed/Series A Labcorp, Quest Diagnostics, Ro, Hims & Hers Home diagnostic testing; predictive gynaecological disease algorithms. Brainomix AI Stroke & Lung Radiology ~$35M Series C Medtronic, Stryker, Viz.ai, Siemens Healthineers e-ACT stroke imaging suite; multiple FDA 510(k) clearances. Alchemab Therapeutics TechBio Antibody Discovery $114M Series A Ext. Eli Lilly, Roche, Sanofi, AstraZeneca Patient-derived antibody discovery platform; strategic Lilly partnership. Patchwork Health Healthcare Workforce IT £27M Series B RLDatix, Allocate Software, PE Platforms End-to-end NHS scheduling; proven labor cost reduction across trusts. Daye Diagnostic FemTech >$21.5M Raised Hologic, Church & Dwight, Procter & Gamble Smart tampon diagnostic platform; STI and microbiome recurring revenue. CoMind Continuous Neuro-monitoring £107.5M Raised (£76.7M Series B) Medtronic, Natus Medical, Integra LifeSciences Non-invasive continuous brain monitoring sensors (CoMind One). Relation Therapeutics Genomic AI Drug Discovery £40.6M+ Raised GSK, Pfizer, AstraZeneca, Novartis Machine learning platform using single-cell tissue data for targets. Limbic Mental Health Clinical AI Venture Backed Headspace, Spring Health, Talkspace, Teladoc Conversational AI triage engine; deep NHS Talking Therapies integration. Scan.com Medical Imaging Marketplace £47M Series B RadNet, InHealth Group, Everlight Radiology Diagnostic scan booking infrastructure operating in UK and US markets. Oxford Cancer Analytics Liquid Biopsy AI Diagnostics £3.7M+ Follow-on Guardant Health, Exact Sciences, Illumina Early-stage multi-cancer biomarker detection algorithms. QV Bioelectronics Bioelectric Oncology Devices £2M+ Pre-Seed/Clinical Novocure, Boston Scientific, LivaNova Implantable Electric Field Therapy (GRACE) for glioblastoma treatment. Lifebit Biotech Federated Biomedical Data VC / PE Backed IQVIA, Thermo Fisher Scientific, Illumina Federated data architecture powering Genomics England and biopharma. Granular Deep-Dive Analysis of Target Companies Cluster A: TechBio & AI-Driven Drug Discovery Platforms 1. CHARM Therapeutics Founded in London and backed by leading life science investors including New Enterprise Associates, SR One, OrbiMed, Khosla Ventures, F-Prime, and NVIDIA’s NVentures vehicle, CHARM Therapeutics secured an $80 million Series B funding round (bringing total capital raised to $130 million). CHARM utilizes its proprietary 3D deep-learning platform, DragonFold, to predict protein-ligand co-folding structures and target disease pathways historically considered "undruggable". Attribute Profile Details Core Technology DragonFold 3D deep-learning platform; CHM-029 menin inhibitor pipeline asset. Total Funding $130 Million ($80 Million Series B led by NEA and SR One). Strategic Acquirers Bristol Myers Squibb, Eli Lilly, Novartis, AstraZeneca. Key M&A Driver Offers Big Pharma a computational discovery engine to address impending patent cliffs. The company's lead asset, CHM-029, is a next-generation menin inhibitor engineered to overcome known resistance mutations in acute myeloid leukemia (AML). With Investigational New Drug (IND) enabling studies supporting clinical trials, CHARM represents a strategic bolt-on candidate for global biopharmaceutical corporations seeking de-risked oncology assets. NVIDIA’s strategic equity participation highlights CHARM’s positioning at the intersection of high-performance compute infrastructure and structural biology. 2. Alchemab Therapeutics Based in Cambridge, Alchemab Therapeutics focuses on discovering novel antibody therapeutics by analyzing resilient patient cohorts who naturally withstand severe neurodegenerative diseases and cancers. Alchemab extended its Series A financing to $114 million, anchored by a €29.3 million equity commitment from the British Business Bank. The company has established a multi-target research collaboration with Eli Lilly to co-develop antibody candidates. By converting naturally occurring protective human antibodies into therapeutic leads, Alchemab offers cross-border pharmaceutical acquirers a de-risked discovery pipeline backed by prospective clinical validation. 3. Relation Therapeutics London-based Relation Therapeutics integrates human genetics, single-cell genomics, and machine learning to analyze disease biology directly in human tissue. Having raised over £40.6 million in seed and Series A capital, Relation generates high-resolution functional genomic datasets to map target pathways. As global pharmaceutical incumbents shift away from traditional animal models toward human-derived data engines to improve clinical trial success rates, Relation is positioned for acquisition by multinational biopharma players (e.g., GSK, Pfizer, AstraZeneca) seeking target discovery platforms. 4. Lifebit Biotech Lifebit provides federated data management and analytics software designed to un-silo sensitive biomedical and genomic datasets for global research institutions. Serving as the underlying technology engine for public-private initiatives such as Genomics England, Lifebit enables pharmaceutical companies to execute AI algorithms across distributed biobanks without moving raw data files. With data sovereignty and privacy mandates tightening across European and US jurisdictions, Lifebit’s federated platform represents a critical infrastructure acquisition for clinical research organizations (CROs) or healthcare data providers like IQVIA, Thermo Fisher Scientific, or Illumina. Cluster B: Regulated AI Diagnostics, Imaging & SaMD Moats 5. Ultromics Spun out of the University of Oxford, Ultromics develops AI-driven echocardiography software designed to diagnose early-stage heart failure and complex cardiovascular conditions. The company's EchoGo platform leverages deep learning models trained on large echocardiogram datasets gathered through Oxford and Mayo Clinic partnerships. Ultromics raised a £41 million Series C funding round (total capital near £100 million) and secured FDA Breakthrough Device designation alongside selection for the FDA's Total Product Life Cycle Advisory Program (TAP) Pilot cohort. Attribute Profile Details Core Technology EchoGo AI echocardiography software (EchoGo Core, EchoGo Amyloidosis). Total Funding ~$100 Million (£41 Million Series C led by Plural). Regulatory Clearances FDA 510(k) Clearances, FDA Breakthrough Designation, FDA TAP Pilot inclusion. Strategic Acquirers GE HealthCare, Siemens Healthineers, Philips Healthcare. Key M&A Driver Pfizer amyloidosis partnership; Medicare reimbursement; routine US clinical deployment. Ultromics’ EchoGo Amyloidosis algorithm—developed in strategic partnership with Pfizer—automates the detection of cardiac amyloidosis from routine ultrasound scans. Supported by established Medicare reimbursement codes and active adoption across top US hospital networks, Ultromics represents a target for medical imaging conglomerates seeking to embed AI decision-support tools into diagnostic hardware systems. 6. Brainomix Oxford-based Brainomix specialises in AI-powered MedTech software that processes CT and MRI scans to automate diagnostic decisions in stroke and interstitial lung disease. Its flaghip e-ACT platform is integrated across acute stroke networks in the UK, Europe, and the United States, reducing door-to-treatment times for ischemic stroke patients. Brainomix completed a Series C funding round to expand its FDA-cleared product offerings into lung disease and virtual clinical trial analytics. MedTech conglomerates and clinical trial software providers view Brainomix as a target capable of enhancing acute imaging workflows. 7. CoMind CoMind is building continuous, non-invasive neural monitoring hardware and software infrastructure. Having raised £76.7 million in Series B funding (total capital £107.5 million), the company is advancing its lead technology, CoMind One, toward commercial deployment. By applying machine learning algorithms to optical sensor data, CoMind enables clinicians to measure real-time cerebral oxygenation and intracranial pressure at the bedside without invasive neurosurgery. CoMind presents an acquisition target for neuro-device manufacturers (e.g., Medtronic, Natus Medical, Integra LifeSciences) seeking to defend hardware market shares with continuous monitoring software. 8. Oxford Cancer Analytics Oxford Cancer Analytics (OXCA) develops machine-learning liquid biopsy technologies for early multi-cancer detection. Following a £3.7 million follow-on funding round, OXCA expanded its biomarker discovery pipeline targeting high-mortality cancers (such as lung and ovarian) using proteomics and cell-free DNA analytics. Global diagnostic leaders (e.g., Guardant Health, Exact Sciences, Illumina) seeking early-stage, capital-efficient liquid biopsy engines represent the logical acquirers for OXCA’s intellectual property portfolio. Cluster C: NHS Primary Care Infrastructure & Workforce Automation 9. Accurx Accurx serves as the core communication and workflow orchestration platform across UK primary care. The platform is utilized by over 98% of GP practices and 68% of NHS acute trusts in England, while expanding across Scotland via dedicated contract frameworks. Originally funded by Lakestar, Atomico, and British Patient Capital through a £27.5 million Series B round ($50 million total raised), Accurx connects primary care teams, secondary care providers, and patients via secure messaging, self-booking links, and structured video consultations. Attribute Profile Details Core Technology Primary care communication platform, Patient Triage, Accurx Scribe (ambient AI). Total Funding ~$50 Million (£27.5 Million Series B). Market Penetration 98% of English GP practices, 68% of NHS trusts, 130+ Scottish practices. Strategic Acquirers Epic Systems, Oracle Health, Dedalus Group, Teladoc Health. Key M&A Driver Dominant UK primary care distribution channel; integrated ambient AI layer. Accurx’s integration of "Accurx Scribe"—an ambient AI clinical documentation tool deployed in partnership with Tandem Health—reaches over 200,000 active NHS healthcare professionals. Because Accurx maintains direct interoperability into legacy Electronic Health Record (EHR) systems (EMIS, SystmOne), it represents a candidate for US enterprise EHR vendors (Epic, Oracle Health) or European IT consolidators (Dedalus Group) seeking dominance over UK clinical care workflows. 10. Patchwork Health Founded by NHS clinicians, Patchwork Health offers end-to-end healthcare workforce management software designed to mitigate clinical staffing shortages. Patchwork raised a £27 million Series B round led by Perwyn and Praetura Ventures. The platform connects NHS trusts with internal and regional bank networks to fill vacant shifts, saving over £120 million in agency staffing costs across 56 healthcare organizations. With healthcare labor shortages persisting globally, private equity-backed workforce platforms (such as RLDatix or Allocate Software) view Patchwork as a bolt-on candidate to consolidate back-office operational software. 11. Scan.com Scan.com operates a digital marketplace and infrastructure layer connecting patients, private providers, and referring clinicians with medical imaging facilities (MRI, CT, Ultrasound) across the UK and the United States. Having secured £47 million in Series B funding backed by Felix Capital, Seedcamp, and Sony Innovation Fund, Scan.com streamlines private diagnostic scheduling. As health systems shift toward outpatient diagnostic centers, imaging network operators (RadNet, InHealth) or digital health aggregators represent prospective strategic acquirers. Cluster D: Virtual Wards, Remote Monitoring & Bioelectronics 12. Doccla Doccla is a pioneer of "virtual wards" and remote patient monitoring across Europe. The company raised $45.9 million in Series B funding to scale its hospital-at-home technology. Doccla equips post-acute patients with tailored medical hardware, wearable biosensors, and smartphone applications that stream real-time physiological data to centralized clinical dashboards. Attribute Profile Details Core Technology Virtual ward operating system; connected remote wearable monitoring software. Total Funding $45.9 Million Series B. Strategic Acquirers Philips Healthcare, Baxter, Humana, Best Buy Health. Key M&A Driver Aligned with NHS "Left Shift" policy; proven reduction in acute hospital admissions. By reducing hospital length-of-stay and readmission rates for the NHS, Doccla aligns directly with UK public health policy mandates. Cross-border MedTech and care delivery acquirers (Philips Healthcare, Baxter, Humana, Best Buy Health) seeking established clinical delivery networks represent natural buyers. 13. Huma Therapeutics Huma has transitioned from a remote monitoring start-up into a prominent digital health aggregator platform. Operating as a scale-up with over $300 million in cumulative capital (including its Series D round), Huma powers hospital-at-home models and decentralized clinical trials globally through its Huma Cloud Platform. Huma has pursued an active M&A strategy, acquiring assets such as eConsult (primary care triage platform serving 1,800 practices), Aluna (FDA-cleared respiratory device), and iPLATO to consolidate patient care pathways from initial digital intake to continuous virtual care. While Huma maintains a dual-track option for a London Stock Exchange IPO, its compliance infrastructure, clinical datasets, and cross-border commercial contracts position it as an acquisition target for life science groups (Roche, Abbott) or US payor-providers seeking an instant European digital care footprint. 14. QV Bioelectronics Manchester-based QV Bioelectronics is developing surgically implanted bioelectronic devices for cancer treatment. Its lead candidate, GRACE, is an Electric Field Therapy (EFT) device designed to continuously target dividing glioblastoma brain tumor cells without damaging surrounding healthy tissue. Supported by clinical research grants and private venture backing (£2 million pre-seed/seed rounds), QV Bioelectronics addresses an underserved neuro-oncology market. Bioelectric device leaders like Novocure or Boston Scientific represent strategic acquirers once early clinical safety data is established. Cluster E: Women’s Health, FemTech & Specialty B2B Platforms 15. Peppy London-based Peppy is a B2B personalized digital health platform focused on specialized healthcare areas including menopause, fertility, women's health, and men's health. Peppy raised $45 million in a Series B funding round led by AlbionVC, alongside Kathaka, MTech Capital, Simplyhealth, and Sony Innovation Fund, explicitly to fuel its enterprise expansion into the US market. Attribute Profile Details Core Technology B2B corporate digital health platform (menopause, fertility, men's health). Total Funding $45 Million Series B. Key Enterprise Clients JP Morgan, Accenture, Disney, TJX; partners with AXA and Vitality. Strategic Acquirers Teladoc Health, Accolade, Hims & Hers, Personify Health. Key M&A Driver Category leader in B2B menopause care; US commercial traction; strong unit margins. Peppy serves over 250 enterprise clients—including JP Morgan, Accenture, TJX, and Disney—while partnering with major insurers like AXA and Vitality to cover more than two million lives. With the global menopause market expanding rapidly and women's health moving into mainstream corporate benefit stacks, Peppy represents an acquisition target for US digital health platforms (Teladoc, Accolade, Hims & Hers, Personify Health) seeking to incorporate employer-funded specialized clinical care. 16. Hertility Health Hertility Health operates in predictive reproductive healthcare and virtual gynecology. Having closed a £4.2 million seed round led by LocalGlobe and Venrex, Hertility provides home diagnostic blood testing alongside proprietary algorithms to detect gynaecological conditions (PCOS, endometriosis, reduced ovarian reserve). By embedding its triage engines directly into clinical care pathways, Hertility accelerates diagnostic timelines for patients. As diagnostic testing consolidators and consumer digital health platforms prioritize specialized care, Hertility represents a strategic bolt-on target for groups like Labcorp, Quest Diagnostics, or Ro. 17. Daye London-based Daye is a diagnostic femtech company known for inventing the diagnostic "smart tampon". Daye has raised over $21.5 million to commercialize its non-invasive screening platform, which enables women to test for vaginitis, STIs, and microbiome imbalances using self-collected samples. Combining a direct-to-consumer recurring subscription business model with diagnostic testing capabilities, Daye sits at the intersection of consumer health and regulated MedTech. Consumer health conglomerates (Hologic, Procter & Gamble, Church & Dwight) are prime acquirers looking to expand their specialty women's health portfolios. Cluster F: Next-Generation Clinical AI & Surgical Platforms 18. CMR Surgical Headquartered in Cambridge, CMR Surgical is Europe’s premier surgical robotics scale-up, having raised over $1 billion in private funding (valued between $3.0 billion and $4.0 billion). The company’s flagship product, the Versius robotic surgical system, offers a versatile, modular footprint designed to fit into standard operating rooms for minimal access surgery. CMR raised $200 million in financing to accelerate commercial distribution across the US and Asia. Attribute Profile Details Core Technology Versius modular robotic surgical system for minimal-access surgery. Total Funding >$1.0 Billion Raised ($200 Million latest round) / ~$3.0B–$4.0B Valuation. Strategic Acquirers Medtronic, Stryker, Johnson & Johnson. Key M&A Driver Dual-track sale vs IPO process; modular footprint enabling broad hospital penetration. Reports confirm that CMR engaged investment advisors to explore a dual-track process, weighing a potential strategic sale valued at ~$4.0 billion against an international public listing. MedTech giants (Medtronic, Stryker, Johnson & Johnson) seeking to compete against Intuitive Surgical’s market position view CMR as a transformational acquisition opportunity. 19. TORTUS TORTUS develops ambient voice software designed to eliminate administrative burdens for clinicians. In June 2026, TORTUS became the first ambient voice tool to achieve Class IIa Software-as-a-Medical-Device (SaMD) certification. The software passively captures doctor-patient consultations, generates structured clinical notes, and populates background EHR systems in real time. As global enterprise healthcare providers prioritize ambient intelligence tools, TORTUS’s Class IIa regulatory status creates a defensive moat. US platforms (Microsoft/Nuance, Commure, Abridge, 3M Health Information Systems) seeking verified UK and European regulatory clearance represent key potential acquirers. 20. Limbic Limbic develops clinical AI conversational software designed to streamline psychological triage and patient intake. The platform is embedded across NHS Talking Therapies services, supporting over 30% of all mental health self-referrals in England. Limbic's triage engine reduces waiting lists, lowers administrative costs, and improves clinical access for underrepresented demographics. Given the growing focus on value-based mental health outcomes, international virtual behavioral health platforms (Headspace, Spring Health, Talkspace) view Limbic as an acquisition target to automate care routing and intake. Strategic Acquirer Archetypes & Cross-Border Execution Mechanics Acquiring entities across the UK healthtech sector fall into four primary buyer archetypes, each driven by distinct strategic imperatives and transaction structures: Global Biopharmaceuticals Multinational pharmaceutical corporations such as Eli Lilly, Bristol Myers Squibb, Roche, Sanofi, AstraZeneca, and Pfizer face substantial revenue cliffs as primary patents expire across biological blockbusters through the late 2020s. To offset these drops, biopharma acquirers are executing "offensive" bolt-on acquisitions of TechBio discovery engines. Rather than entering temporary research licensing agreements, biopharma buyers are absorbing computational drug design platforms (e.g., CHARM, Alchemab, Relation) to internalise proprietary target validation capabilities, de-risk pipelines and shorten early-stage development cycles. MedTech and Diagnostic Conglomerates Hardware manufacturers including GE HealthCare, Siemens Healthineers, Medtronic, Stryker, Abbott, and Philips Healthcare are experiencing margin pressures on traditional physical diagnostic hardware and surgical equipment. Acquiring regulated SaMD platforms (e.g., Ultromics, Brainomix, CoMind, CMR Surgical) allows these conglomerates to bundle advanced AI decision-support tools directly into hardware sales, effectively transitioning commercial models toward recurring, high-margin software subscriptions. US Digital Health Platforms and Payor-Providers Public US digital health platforms and managed care organisations, such as Teladoc Health, Hims & Hers, Accolade, Commure, Elevance Health and Humana are actively expanding into B2B employer channels and international regions. Acquiring established UK platforms (e.g., Peppy, Huma, Doccla, Accurx) provides immediate revenue diversification, access to corporate client portfolios (such as JP Morgan, Accenture, and Disney), and established NHS operational contracts. Financial Sponsors & Private Equity Roll-Up Platforms Private equity firms including Bain Capital, Nordic Capital, Summa Equity, and Perwyn are aggressively exploiting lower-mid-market fragmentation across UK healthcare IT. Financial sponsors utilise buy-and-build strategies to consolidate back-office software point solutions (e.g., Patchwork Health flexible scheduling) into unified digital operating platforms, optimizing unit margins and positioning the combined entities for secondary sales to global strategics. Macro Impact and Multi-Order Market Effects The surge in cross-border M&A across the UK healthtech landscape generates several distinct second and third-order ripple effects across the broader healthcare economy. Primary cross-border buyouts of UK healthtech IP create immediate liquidity events for domestic venture capital funds and academic spin-out programs. This capital recycles back into the ecosystem, funding early-stage research clusters surrounding Oxford, Cambridge, and London. However, a secondary effect involves the geographic relocation of commercial headquarters to the United States. Acquirers frequently re-domicile executive leadership to North America to capture higher commercial reimbursement rates from private US payors, leaving UK facilities operating primarily as specialized R&D centers. Concurrently, the acquisition of UK digital care platforms (such as Doccla, Accurx, and Huma) by global healthcare conglomerates accelerates the operational transformation of the NHS. International buyers supply capital, enterprise cybersecurity, and operational scale, allowing once-fragmented point solutions to deploy across regional Integrated Care Systems (ICSs). This private capital deployment supports the NHS 10-Year Health Plan's "Left Shift," permanently transferring patient management from hospital wards to home monitoring networks. Finally, the emphasis placed by international buyers on "compliance moats" is forcing early-stage UK healthtech startups to integrate regulatory compliance directly into initial product architectures. Rather than treating MHRA, FDA, or EU MDR certification as delayed milestones, founders are designing compliance-first platforms from inception. This shift ensures that UK scale-ups remain prime acquisition targets capable of scaling across global healthcare markets. Conclusions The UK healthcare technology sector has entered an execution-led transaction cycle where clinical efficacy, regulatory certification, and workflow integration govern enterprise valuations. For cross-border strategic buyers, spanning US biopharmaceutical companies, global MedTech conglomerates and European healthcare platforms, the UK presents an inventory of clinically validated, regulatory-cleared assets. Over the next 12 months, acquisition activity will remain concentrated within computational drug discovery, SaMD medical imaging, remote virtual wards, and specialised corporate health solutions. Strategic acquirers that move to secure these UK category leaders will establish defensive regulatory moats, absorb critical AI capabilities and capture long-term leadership across the evolving global digital healthcare landscape. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Analysis of Highland Europe’s €1.1 Billion Fund VI Executive Summary and Market Context The European venture capital ecosystem has historically experienced a growth-stage capital deficit, frequently requiring venture-backed enterprises advancing past Series B to access North American capital pools for late-stage expansion. The closing of Highland Europe’s sixth fund vehicle, Fund VI, at €1.1 Billion (~$1.25 Billion USD), represents a structural development in the scale and independence of European growth equity. This vehicle brings the firm's total cumulative capital raised since its 2012 spin-off to €3.75 Billion across six dedicated funds, reinforcing Highland Europe’s central thesis that European technology scale-ups can achieve tier-one global market capitalisation while anchored in European growth capital structures. The deployment of Fund VI occurs alongside an impressive capital return cycle for the firm. Highland Europe generated over €1 billion in total investor liquidity within a single 12-month period. This capital recycling was driven by four major liquidity events across diverse technology verticals: the $3 billion private equity buyout of digital employee experience platform Nexthink; the public listing of application software conglomerate Bending Spoons on NASDAQ (ticker: BSP) at a market capitalisation exceeding $18 billion; the $7.5 billion merger between German fitness technology scale-up EGYM and Playlist;and the agreed acquisition of direct-to-consumer health brand Huel by global food leader Danone. Highland Europe’s investment strategy targets growth-stage companies that have cleared initial product-market fit hurdles, established repeatable commercial models and demonstrated unit economics suitable for international expansion. The firm provides expansion capital to accelerate global operational footprints, strengthen executive leadership teams, and expand product lines. By focusing on critical infrastructure, vertical artificial intelligence, enterprise software, financial tech, agtech, and consumer technology, Fund VI targets scale-ups positioning themselves at the intersection of workflow automation and enterprise digital transformation. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Fund VI Structure, Governance and LP Commitments Highland Europe operates an equal partnership model across dual primary hubs in London and Geneva. The firm’s team comprises 36 members, including 20 specialized investment professionals. Coinciding with the launch of Fund VI, Highland Europe promoted senior investors Helena Richardson and Jacob Bernstein to Partner. Richardson, who joined the firm in 2016, has built investment theses across consumer technology, digital health, and specialized retail brands, backing enterprises such as Huel, Ffern, ME+EM, and Modulr. Bernstein, who joined in 2017, focuses on enterprise software infrastructure, cybersecurity, and deep artificial intelligence platforms, leading deals in Unframe, Zero Networks, Oritain, and Descartes Underwriting. Fund VI was raised primarily from Highland Europe’s existing Limited Partner (LP) base, reflecting LP institutional alignment driven by consistent realised distributions. A notable institutional contribution includes a €65 Million commitment from the British Business Bank, reinforcing public-private institutional backing for growth equity across the United Kingdom and broader European tech sectors. Across its portfolio, Highland Europe oversees assets representing over $6 Billion in aggregate revenue and a global employment footprint exceeding 15,000 to 20,000 workers across more than 80 funded scale-ups. Parameter / Metric Profile & Strategic Value Fund Vehicle Highland Europe Technology Growth Fund VI Target Fund Size €1.1 Billion (~$1.25 Billion USD) Cumulative Assets Raised (2012–Present) €3.75 Billion across 6 Funds Liquidity Generated (2026) > €1.0 Billion returned to Limited Partners Key Anchor Commitments Existing Institutional LPs; €65 Million from British Business Bank Operating Footprint & Team Size London & Geneva; 36 total employees (20 investment professionals) Leadership Structure Equal Partnership; Recent Partner promotions: Helena Richardson & Jacob Bernstein Target Stage & Check Size Growth Equity (Series B to Pre-IPO); Scaled commercial growth capital Aggregate Portfolio Footprint 80+ companies invested, 30 exits, $6B+ cumulative revenue Liquidity Realisation Mechanics: Analysis of Portfolio Exits The realisation of over €1 Billion in investor distributions within a 12-month window highlights Highland Europe's execution across multiple exit vectors, including private equity buyouts, public equity listings, cross-border corporate M&A and strategic consolidation. Strategic M&A transactions provided significant liquidity, as demonstrated by the agreed sale of consumer nutrition brand Huel to French multinational Danone and the $7.5 Billion merger of German fitness technology provider EGYM with Playlist. The EGYM-Playlist combination highlights the trend of combining hardware, corporate health offerings, and fitness SaaS platforms into dominant global health platforms. Concurrently, private equity buyouts offered a stable secondary realization pathway for enterprise software assets. The $3 Billion sale of digital employee experience (DEX) software leader Nexthink to a private equity sponsor underscores institutional demand for high net retention, mission-critical enterprise software businesses operating at scale. Public capital markets provided a high-profile exit channel through the NASDAQ listing of software holding company Bending Spoons under the ticker symbol BSP. Reaching a public market capitalisation exceeding $18 Billion, Bending Spoons' rapid rise validates an operating playbook centred on acquiring established digital platforms, restructuring their underlying technical architecture, and applying centralised AI, data analytics, and monetisation capabilities to expand operating cash flow. Company Sector Transaction Structure Transaction Value / Capitalisation Strategic Implication Bending Spoons App Ecosystem / Software Holding NASDAQ IPO (Ticker: BSP) > $18.0 Billion Market Cap Proves European capability to execute major tech roll-ups and list on US markets. EGYM Fitness Technology / Corporate Wellness Strategic Merger with Playlist $7.5 Billion Combines physical hardware, consumer health, and corporate SaaS into enterprise platforms. Nexthink Digital Employee Experience (DEX) Buyout Sale to Private Equity Sponsor $3.0 Billion Demonstrates strong PE demand for high-ARR, enterprise-grade software infrastructure. Huel Consumer Nutrition / Health Tech Strategic Acquisition by Danone Undisclosed (Agreed Sale) Confirms strategic appetite from global FMCG incumbents for direct-to-consumer health brands. Sectoral Investment Architecture and Portfolio Deep Dives Highland Europe’s Fund V deployment and initial Fund VI allocations reflect a clear thesis: value creation in artificial intelligence is shifting away from generalised model training toward vertical workflow orchestration, specialised application layers, and domain-specific systems of action. The firm’s portfolio is distributed across enterprise AI, workflow orchestration, debt capital markets intelligence, healthcare automation, agtech robotics and edge hardware. Enterprise AI Architecture and Workflow Orchestration Highland Europe’s recent enterprise deployments reflect a distinct preference for platforms that directly capture operational workflows, protecting them from the disintermediation risks common to generic software copilots. Co-founded by CEO Ross McNairn, CTO Volodymyr Giginiak, and COO Robbie Falkenthal, Wordsmith AI provides an operational platform designed for in-house legal departments. Highland Europe led Wordsmith’s $70 Million Series B round alongside Index Ventures, which was supplemented by a $14 Million extension led by Intact Private Capital and FT Ventures, bringing total capital raised to $114 Million. Wordsmith's architectural design targets corporate legal operations rather than law firms. While law firm billable-hour models incentivise manual drafting hours, corporate legal teams prioritise throughput, risk management and bringing external legal work back in-house. Wordsmith integrates directly into corporate communication and business tools, such as Slack, Microsoft Teams, Salesforce, and email, operating under a four-stage process: Receive, Route, Resolve, and Record. AI agents handle routine NDAs, vendor reviews, and privacy questionnaires against company-approved playbooks, surfacing to human lawyers only those matters that require strategic risk evaluation. This approach has supported a 14x year-over-year revenue expansion, securing over 500 enterprise customers, including BT, the Financial Times, Sage, Starling Bank, Canva, and Safelite. Founded by former Noname Security executives Shay Levi and Larissa Schneider, Unframe developed a managed AI delivery platform that assists enterprise clients in transitioning AI applications from pilot concepts into secure production environments. Highland Europe led Unframe’s $50 million Series B round, bringing total capital raised to $100 Million. Unframe addresses the enterprise challenge where AI prototypes stall due to context window limitations, data sovereignty concerns, latency issues and integration overheads. Utilising an outcome-based commercial model, Unframe enables enterprise engineering teams to deploy production-ready AI tools within days. Unframe crossed $100 Million in Total Contract Value (TCV) in under 12 months, supported by a 400% net revenue retention rate, underscoring high enterprise demand for managed AI runtime environments. Headquartered in Berlin and founded by Jan Oberhauser, n8n operates as a fair-code workflow automation and AI orchestration platform. Positioned between fully autonomous AI agents, which can be unpredictable in mission-critical enterprise environments and rigid, code-heavy rule systems, n8n provides a visual canvas that balances deterministic logic with probabilistic agent execution. n8n raised $180 Million in Series C funding led by Accel, with participation from NVentures (NVIDIA’s venture arm) and Highland Europe, valuing the business at $2.5 Billion. Subsequently, German enterprise software provider SAP completed a strategic investment acquiring a ~1.3% equity stake for over €60 Million, doubling n8n’s valuation to $5.2 Billion and making it Germany’s most valuable AI startup. Under a multi-year commercial agreement, n8n is embedded directly into Joule Studio, the agent builder within the SAP Business AI Platform. This integration allows 300,000 SAP enterprise clients to connect Joule AI agents across non-SAP legacy systems using over 1,000 pre-built nodes while preserving strict GDPR, auditability, and data sovereignty controls. With over 1.7 Million active builders, 183,000 GitHub stars, and 3,000 enterprise customers (including Microsoft, Vodafone, Volkswagen, and Mercedes-Benz), n8n represents a core layer of global enterprise orchestration. Vertical Intelligence, FinTech, DeepTech and Hardware Integration Highland Europe’s sector footprint extends into financial data analytics, healthcare automation, agtech robotics, and consumer hardware. Focused on the $141 Trillion global debt capital markets, 9fin is an AI-powered financial intelligence and analytics platform. Founded by Steven Hunter and Huss El-Sheikh, 9fin raised a $50 million Series B round led by Highland Europe, with partner Fergal Mullen joining the company's board of directors. Historically, debt capital markets, comprising high-yield bonds, leveraged loans, private credit, distressed debt and asset-backed securities, have relied on manual data entry and fragmented information systems. 9fin’s platform extracts and standardises over 10 Million data points from earnings transcripts and regulatory filings, offering debt market professionals real-time news, predictive analytics and agentic query tools. Following its Series A+ in 2022, 9fin grew its Annual Recurring Revenue (ARR) by 400%, expanding its client footprint to over 200 institutions, including 9 of the top 10 global investment banks, private credit managers, and law firms representing over $17 Trillion in aggregate AUM. Co-founded by former Facebook AI Research leaders Alexandre Lebrun (CEO), Delphine Groll (COO), and Martin Raison (CTO), Nabla provides an ambient AI clinical assistant. Nabla Copilot operates natively during patient consultations, transcribing and summarising dialogue in real time to generate structured clinical notes that integrate directly into Electronic Health Record (EHR) platforms such as Epic and NextGen. By automating clinical reporting, Nabla reduces documentation time by more than 50%, directly mitigating practitioner burnout. After raising a $24 million Series B in early 2024, Nabla secured a $70 million Series C round led by HV Capital with participation from Highland Europe and DST Global, bringing total capital raised to $120 million. Serving over 85,000 clinicians across 130+ healthcare systems and processing millions of patient visits annually across multiple languages, Nabla is expanding its platform toward real-time medical coding and contextual clinical agents. Swiss agtech scale-up Ecorobotix specializes in Ultra-High Precision (UHP) plant-by-plant crop protection. Co-founded by Steve Tanner and Aurélien Demaurex, and led by CEO Dominique Mégret, Ecorobotix closed a $105 Million Series D funding round led by Highland Europe, bringing its total financing across Series C and D to $150 Million. Ecorobotix developed the ARA sprayer, a tractor-towed system equipped with high-resolution RGB and 3D vision cameras operating alongside proprietary Plant-by-Plant™ AI algorithms. Scanning fields in real time with sub-centimeter accuracy, ARA identifies specific crop and weed species, applying targeted sprays within a 6 x 6 cm footprint. This targeted delivery reduces pesticide, herbicide, and fertilizer consumption by up to 95% compared to broadcast spraying, preserving crop health and boosting yields. Operating in over 20 countries with more than 25 crop algorithms, Ecorobotix offers an operational solution for growers facing regulatory restrictions on agricultural chemicals, rising input costs, and labor shortages. Founded in 2020 by former OnePlus co-founder Carl Pei, consumer electronics brand Nothing aims to create an open hardware-software ecosystem. Highland Europe led Nothing’s $96 million financing round in 2023 and participated in its $200 Million Series C round led by Tiger Global, which valued the company at $1.3 Billion. Nothing has shipped millions of devices globally—including smartphones, smartwatches, and audio products, crossing $1 Billion in cumulative sales. The company focuses on industrial design differentiation (featuring its signature transparent aesthetic and Glyph interface) while developing an AI-native operating system designed to offer context-aware user interfaces across physical hardware categories. Company Vertical Sector Latest Round Size & Primary Lead Select Financial & Operational Metrics Core Value Proposition & Technology Focus Wordsmith AI Legal Operations / Corporate AI $70M Series B (+$14M Ext) led by Highland Europe & Index 14x YoY ARR Growth; 500+ Enterprise clients System of action for in-house legal teams to automate routine contracts and reduce outside counsel spend. Unframe Enterprise AI Delivery & Integration $50M Series B led by Highland Europe > $100M TCV in under 12 months; 400% NRR Managed AI platform converting enterprise LLM pilot projects into production deployments. n8n AI Workflow Orchestration / Developer Tools $180M Series C (Accel); Strategic investment by SAP $5.2B Valuation; 1.7M active builders; 1,400+ Enterprise clients Fair-code workflow canvas enabling deterministic logic and multi-agent AI execution across systems. 9fin Debt Capital Markets Intelligence $50M Series B led by Highland Europe 400% ARR growth; Used by 9 of top 10 investment banks AI-driven analytics extracting 10M+ data points across high-yield, private credit, and loan markets. Nabla Healthcare / Ambient AI Clinical Scribes $70M Series C led by HV Capital (Highland backed) 85,000+ Clinicians; 130+ Health Systems Ambient clinical speech recognition automatically populating structured EHR notes to lower doctor burnout. Ecorobotix Precision Agriculture / AgTech Robotics $105M Series D led by Highland Europe Active in 20+ countries; 25+ plant algorithms Plant-by-Plant™ vision AI spraying system reducing pesticide usage by up to 95%. Nothing Consumer Hardware & AI-Native OS $200M Series C led by Tiger Global (Highland backed) $1.3B Valuation; $1B+ lifetime sales; 5M+ devices shipped Premium consumer electronics ecosystem integrating design with personalized AI hardware experiences. Synthesis and Strategic Implications for European Venture Highland Europe’s €1.1 Billion Fund VI deployment illustrates several key trends within the European growth-stage venture ecosystem: First, the capital realisation cycle achieved by Highland Europe demonstrates that European technology funds can generate liquid returns comparable to tier-one global venture institutions. By executing exits across traditional private equity buyouts (Nexthink), public listings (Bending Spoons), strategic trade sales (Huel/Danone), and large-scale mergers (EGYM/Playlist), the firm shows that liquidity generation is achievable across various market conditions without relying on single exit channels. Second, Highland Europe's investment deployment highlights a deliberate preference for structural workflow layers over commoditized foundation models. The firm's positions in Wordsmith, n8n, 9fin, and Unframe highlight a strategy that prioritizes deep integration into underlying enterprise operations. By controlling proprietary enterprise data, user interfaces, and execution pathways, these platforms insulate themselves from the price erosion and technical obsolescence risks affecting generalized LLM providers. Third, portfolio scaling strategies reflect an emphasis on transatlantic commercial expansion. Rather than remaining limited to domestic European markets, scale-ups such as Wordsmith, 9fin, Nabla, and Ecorobotix utilise growth capital to establish operational footprints in North America early in their expansion phases. This strategy allows European scale-ups to maintain engineering hubs across European technology centers while commercializing their platforms across high-contract-value enterprise segments in the United States. Conclusion Highland Europe’s €1.1 billion Fund VI reflects the maturing structure of the European growth equity market. Supported by institutional limited partners and driven by a capital recycling mechanism that delivered over €1 Billion in distributions, the firm’s equal partnership structure provides growth capital across software, AI, and hardware scale-ups. By prioritising domain expertise, deep enterprise integration, and global expansion, Fund VI provides a strategic framework for scaling European technology companies into global market leaders. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Wall Street switches from Tech to Healthcare Capital Rotation into US Healthcare: Evaluating Market Dynamics, Valuations and Earnings Inflections amid Tech Trade Turbulence A notable structural reallocation of institutional capital has accelerated across global equity markets. Investors are increasingly systematically reducing overextended allocations in heavy-technology equities and redeploying liquidity into U.S. healthcare stocks. This sector rotation comes as the long-running mega-cap technology rally encounters heightened volatility, driven by growing institutional skepticism surrounding multi-billion-dollar artificial intelligence (AI) capital expenditure (CapEx) buildouts and escalating corporate debt issuance. While major stock market indexes continue to trade near historically elevated levels, underlying market breadth reveals a meaningful expansion. Market participants are seeking downside protection, valuation discipline, and reliable operational growth outside the concentrated technology ecosystem. Healthcare equities have stepped into the fore, supported by attractive forward price-to-earnings (P/E) valuations relative to the broader S&P 500, resilient dividend yields and a wave of strong second-quarter 2026 corporate earnings beats and guidance upgrades across large-cap pharmaceuticals, biotechnology, and managed care organisations. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Macroeconomic Drivers and the AI Capital Expenditure Dilemma The primary catalyst behind the August 2026 sector shift is the emerging friction within the technology trade. Over the preceding eight quarters, mega-cap technology companies committed record levels of capital to AI infrastructure, semiconductor acquisition, and data center construction. However, market participants are scrutinising these massive capital commitments with increasing rigour, questioning the medium-term timeline for return on invested capital (ROIC) and revenue conversion. This CapEx burden has coincided with extreme index concentration. Semiconductor equities alone expanded to represent approximately 42% of the S&P 500 Information Technology sector and nearly 20% of the entire benchmark index. This narrow market leadership left passive and active portfolios alike heavily exposed to single-factor momentum risks. As the Federal Reserve pauses its interest rate easing cycle amid sticky baseline inflation, elevated borrowing costs have exacerbated concerns over debt-financed tech CapEx, triggering widespread profit-taking across overextended tech names like Nvidia, Microsoft, Broadcom, and Apple. Sector Ticker Sector Name Relative Momentum Status Forward 12-Month P/E Ratio Institutional Allocation Trend (Q3 2026) Primary Macro & Fundamental Drivers XLK Information Technology Weakening / Cooling ~28.5x Moderate Outflows ($1.57B weekly inflow low) Scrutiny on AI CapEx payback, high debt, concentration risk XLV Health Care Rebounding / Leading ~18.0x Significant Inflows ($2.44B net in July 2026) Low market beta, strong Q2 beats, MLR recovery, GLP-1 expansion XLP Consumer Staples Leading ~19.2x Steady Value Inflows ($3.0B value fund influx) Flight-to-safety asset, sticky consumer demand, dividend security XLE Energy Leading ~14.1x Net Institutional Accumulation Inflation hedge, elevated global crude prices, data center power demand XLF Financials Strengthening ~15.4x Broad Capital Inflow Sustained elevated net interest margins, resilient economic activity The systemic rebalancing is clearly illustrated by weekly fund flow metrics. Investors withdrew $7.18 Billion from U.S. growth funds in late July and early August 2026, reversing previous net inflows. Conversely, value-oriented equity funds recorded $3.0 Billion in net weekly inflows, extending a three-week trend toward defensive asset classes. Healthcare funds emerged as a primary beneficiary, absorbing $2.44 Billion in July 2026 alone after pulling in $1.5 Billion in June, effectively reversing a prior three-month drawdown streak. Bank of America’s Global Fund Manager Survey corroborated this shift, revealing that institutional managers surged to a net 32% overweight position in healthcare stocks in July 2026, up dramatically from 14% in June. From a structural perspective, the friction in tech CapEx is generating positive ripple effects for non-tech sectors. Rather than absorbing the high cost of foundational model development, healthcare operators are deploying mature, off the shelf AI applications to streamline claims processing, automate clinical workflows, and optimise drug discovery pipelines. Consequently, capital is migrating from the infrastructure builders facing compressed margins toward operational adopters capable of capturing immediate efficiency gains. Defensive Valuation Asymmetry and Portfolio Construction Mechanics The institutional preference for healthcare equities is strongly reinforced by relative valuation metrics. Following a prolonged period of tech leadership where defensive sectors were largely unloved, the healthcare sector traded at a severe discount to the broader market. In mid-2026, the S&P 500 Healthcare sector traded at approximately 18 times its 12-month forward earnings expectations. Although this sits slightly above its 20 year historical average of 15 times forward earnings, it represents a discount to the overall S&P 500 forward valuation of nearly 20 times and a stark discount to mega-cap technology multiples exceeding 28 to 35 times forward earnings. Institutional portfolio managers are using healthcare’s structural low beta profile to insulate portfolios against macro volatility. Factor based risk models indicate that large cap pharmaceuticals and health insurance providers maintain market betas ranging between 0.65 and 0.75, making them effective risk mitigants during technology pullbacks. Furthermore, steady dividend yields across the healthcare space, typically averaging between 1.5% and 2.5%, provide institutional accounts with income equity buffers during periods of interest rate and equity price uncertainty. Asset / Index Forward P/E Multiple Dividend Yield (%) Market Beta 3-Month Trailing Return Key Structural Role in Portfolio Construction S&P 500 Index ~20.0x ~1.35% 1.00 +6.0% Core market benchmark S&P 500 Tech (XLK) ~28.5x ~0.70% 1.25 +2.1% Growth engine subject to CapEx re-evaluation S&P 500 Healthcare (XLV) ~18.0x ~1.85% 0.70 +11.2% Low-beta growth compounder and flight-to-safety hedge Min. Volatility ETF (USMV) ~17.5x ~2.10% 0.70 +7.4% Factor-based downside risk mitigation vehicle This macro alignment is further supported by expected multi-year corporate earnings trajectories. While healthcare suffered a temporary 16.7% earnings contraction in the second quarter of 2026 due to lingering post-pandemic care adjustments and integration costs, consensus macroeconomic forecasts project double digit earnings growth for S&P 500 healthcare companies starting in the fourth quarter of 2026 and extending throughout 2027. The expectation of accelerating operational tailwinds alongside relative valuation discounts creates a compelling setup for multi-quarter sector outperformance. Fundamental Catalysts: Q2 2026 Earnings Beats and Guidance Upgrades The strategic thesis for healthcare has been strongly validated by second-quarter 2026 financial releases. High-profile corporate beats across pharmaceuticals, pharmacy retail and managed care have reassured investors about core operational health, providing strong catalyst support for the ongoing rotation. Company Ticker Key Q2 2026 Financial Results Full-Year 2026 Guidance Revisions Core Operational Drivers & Strategic Highlights Eli Lilly & Co. (LLY) Q1/Q2 revenue prints surpassing $19.8B (+56% YoY); EPS $8.55 vs $6.97 est. Revenue guidance raised to $85.0B–$87.0B; Adj. EPS $35.50–$37.00 Relentless demand for GLP-1 portfolio (Mounjaro $8.66B, Zepbound $4.16B); Foundayo oral launch CVS Health Corp. (CVS) Q2 Adj. EPS $2.58 vs $1.85 est.; Consolidated Revenue $106.1B (+7.3% YoY) Full-year Adj. EPS raised to $7.90–$8.10; Revenue ≥ $414.0B Aetna MLR improvement to 87.4%; retail pharmacy expansion; Eli Lilly GLP-1 distribution partnership UnitedHealth Group (UNH) Q2 Adj. EPS $6.38 vs $4.85 est. (+30% surprise); Revenue $112.03B Full-year Adj. EPS raised to $19.50–$20.00; OCF ~$24.0B MCR collapsed to 86.7% (from 89.4%); Optum Health margin expansion; $5B share buyback target AbbVie Inc. (ABBV) Q2 Revenue and EPS topped consensus projections Outlook reaffirmed/adjusted post-$10.9B Apogee transaction Expansion in non-Humira immunology franchise (Skyrizi, Rinvoq) and targeted oncology assets Eli Lilly and the Metabolic Therapeutics Boom Eli Lilly and Company continues to act as an anchor growth engine for the broader pharmaceutical sector. Fuelled by demand for its cardio-metabolic portfolio, Eli Lilly upgraded its full-year 2026 revenue guidance to an unprecedented range of $85.0 Billion to $87.0 Billion. The driver behind this expansion is the company’s dual GLP-1/GIP receptor agonist molecule, tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. In recent quarterly prints, Mounjaro generated $8.66 Billion in global sales, a 125% year-over-year surge, officially surpassing Merck’s cancer immunotherapy Keytruda as the world's top-selling prescription drug. Zepbound contributed an additional $4.16 Billion in U.S. revenues, bringing the combined quarterly revenue of the tirzepatide franchise to $12.8 Billion. Eli Lilly currently commands over 60% of the U.S. GLP-1 obesity and diabetes market, widening its lead over primary competitor Novo Nordisk, which has faced growth friction and supply limitations. To consolidate its market dominance, Eli Lilly launched Foundayo (orforglipron), its FDA-approved daily oral GLP-1 receptor agonist. Unlike rival oral semaglutide formulations that require strict fasting protocols with water, Foundayo can be administered without food or fluid restrictions, providing a significant compliance advantage. Furthermore, Eli Lilly’s next generation triple agonist candidate, retatrutide, targeting GIP, GLP-1, and glucagon receptors, successfully achieved all primary endpoints in Phase 3 trials, promising even higher efficacy for metabolic disease management. CVS Health and Managed Care Cost Stabilisation CVS Health Corporation delivered a major earnings beat, serving as a primary signal of operational recovery across health services and pharmacy retail. CVS reported Q2 2026 adjusted earnings per share of $2.58, beating the analyst consensus of $1.85 by nearly 40%. Consolidated revenues rose 7.3% year over year to $106.1 Billion, outpacing expectations of $100.03 Billion. On the back of these operational results, CVS raised its full-year adjusted EPS forecast to $7.90–$8.10 per share (up from $7.30–$7.50) and elevated its full-year revenue guidance to at least $414 Billion. A key focus for market participants was the operational turnaround within CVS’s health insurance arm, Aetna. The unit reported a Medical Loss Ratio (MLR) of 87.4% for Q2 2026, marking a substantial improvement from 89.9% in the prior-year period. This drop in MLR demonstrates tighter medical cost management, underwriting price corrections and the stabilisation of post-pandemic outpatient care utilisation. Strategically, CVS Health announced a landmark partnership with Eli Lilly. Under this arrangement, CVS integrated direct access to Eli Lilly’s GLP-1 medications, Zepbound and Foundayo, into the CVS Health digital application. The platform provides direct cash-pricing transparency and enables same-day prescription pickup across CVS's network of approximately 9,000 retail pharmacies, positioning CVS as an essential distribution partner in the obesity care landscape. UnitedHealth Group and Underwriting Recovery UnitedHealth Group (UNH) reinforced the managed care recovery thesis by delivering a significant quarterly beat. UNH reported Q2 2026 adjusted EPS of $6.38, crushing consensus expectations of $4.85–$4.94 by over 30%. Revenues reached $112.03 Billion, supported by solid performance in both UnitedHealthcare and Optum. UNH’s Medical Care Ratio (MCR) collapsed to 86.7% from 89.4% in Q2 2025, beating Wall Street estimates of ~88.6%. This margin expansion allowed management to raise full-year 2026 adjusted EPS guidance to $19.50–$20.00 per share, project operating cash flow of ~$24.0 Billion and increase its share repurchase target to at least $5.0 billion. The company's Optum division saw margin expansion as Optum Health re-centred its core operations around integrated, value-based care delivery models. Wall Street switches from Tech to Healthcare Structural Industry Shifts: Managed Care Stabilisation and M&A Acceleration The operational recovery across healthcare is being further propelled by two major structural drivers: the stabilisation of medical cost ratios across health insurers, and a surge in strategic corporate consolidation. Medical Care Ratio Stabilisation Mechanics Throughout late 2024 and 2025, health insurers struggled with elevated Medical Loss Ratios (MLRs), driven by an unexpected surge in senior outpatient surgical procedures and aggressive provider coding strategies under the No Surprises Act Independent Dispute Resolution (IDR) framework. By mid-2026, managed care organisations successfully counteracted these margin pressures through multi-quarter strategic interventions: Underwriting Repricing: Insurers implemented mid-to-high single-digit premium rate increases across Medicare Advantage, Commercial, and ACA Marketplace plans, re-aligning premium revenue with underlying medical cost inflation. Care Plan Redesign: Health plans restructured benefit frameworks to encourage high-efficiency, outpatient value-based care pathways, reducing costly acute hospital readmissions. Predictable Utilisation Patterns: Outpatient elective procedure rates normalised toward historical baselines, allowing actuarial teams to price risk with greater precision. This stabilisation transformed managed care organisations from compressed-margin entities into strong cash-flow generators, restoring investor confidence across the health services domain. Strategic Mergers and Acquisitions Velocity In parallel with fundamental earnings beats, healthcare consolidation has accelerated at a rapid pace. Total merger and acquisition (M&A) deal value in healthcare reached nearly $284 Billion through early August 2026, closing in on the $306 bBillion recorded across all of 2025 and setting the fastest pace since 2021. Large-cap pharmaceutical companies are leveraging healthy balance sheets to acquire clinical-stage biopharmaceutical assets, aiming to replace revenues threatened by upcoming loss-of-exclusivity (LOE) events. A primary example includes AbbVie’s $10.9 Billion acquisition of Apogee Therapeutics to bolster its post-Humira immunology pipeline. Furthermore, capital markets are pricing in potential mega-merger activity. Market reports revealed exploratory merger discussions between AstraZeneca and Bristol Myers Squibb. A combination of these two pharma leaders would create an entity valued at nearly $400 Billion, consolidating leading global market share across oncology, cardiovascular and metabolic therapeutic sectors. M&A Deal / Rumoured Transaction Target / Combined Entity Estimated Value ($B) Strategic Imperative & Market Impact AbbVie / Apogee Therapeutics Apogee Therapeutics $10.9 Billion Bolster post-Humira immunology franchise; acquire novel clinical assets AstraZeneca / Bristol Myers Squibb Combined Entity ~$400.0 Billion Mega-merger to dominate global oncology, cardiovascular, and cell therapy markets Broad Industry Aggregation Clinical-Stage Biotech Assets $284.0 Billion (YTD) Pipeline replenishment ahead of late-2020s patent cliffs; utilization of strong cash flow Political and Policy Scenarios: Midterm Election Dynamics As the November 2026 U.S. midterm elections approach, health policy dynamics are taking center stage in portfolio stress-testing. Institutional investors are evaluating equity exposures against two primary political outcomes: Democratic Control of the House of Representatives: Should Democrats regain control of the House, legislative priorities are expected to center on expanding Affordable Care Act (ACA) premium subsidies, increasing federal Medicaid matching grants, and resisting efforts to scale back healthcare coverage mandates. Econometrically, this scenario is highly favourable for acute-care hospital systems and Medicaid-focused managed care providers, as it guarantees high insured patient volumes and minimises bad-debt charity care burdens. Divided Government / Republican Legislative Retention: Market strategists generally regard a divided government in Washington as the most bullish tailwind for large-cap pharmaceuticals and commercial health insurers. Legislative gridlock effectively eliminates the threat of sweeping regulatory overhauls, caps expansion of federal drug price negotiation frameworks, and preserves private market pricing flexibility across pharmaceutical portfolios. By factoring these political scenarios into financial models, institutional allocators view the healthcare sector as uniquely positioned: benefiting from policy tailwinds in a coverage-expansion scenario, while enjoying regulatory stability under divided government. Synthesis and Portfolio Recommendations The rotation of capital from heavy-technology equities into U.S. healthcare stocks represents a rational portfolio realignment driven by macro conditions, valuation disparities, and fundamental earnings strength. High CapEx debt commitments and extreme index concentration within tech have led investors to seek downside protection without sacrificing quality growth. Healthcare fulfills these portfolio criteria. The sector offers a discount to broader index valuations (~18x forward P/E), low market beta (0.65–0.75), reliable dividend yields, and accelerating operational momentum. Multi-billion-dollar GLP-1 therapeutic expansion, normalised Medical Loss Ratios across managed care organisations, and a multi-year high in M&A volume confirm that healthcare’s fundamental outlook is robust. Institutional investors are likely to maintain elevated healthcare allocations through late 2026 and into 2027, leveraging the sector's balance of defensive characteristics and compounding earnings growth to navigate ongoing market turbulence. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Google Health 5.05 and Apple HealthKit Interoperability Executive Summary and Historical Context The digital health ecosystem has historically been defined by platform fragmentation, walled gardens, and restricted data portability. Since the launch of Apple HealthKit alongside iOS 8 in 2014, major wearable and software vendors have leveraged health metrics as a primary mechanism for customer retention. Fitbit and subsequently its parent entity, Google, maintained a constrained interoperability posture on iOS. While third-party utilities filled the gap by bridging background data transfers, native data write-backs from Google’s wearable stack into Apple’s centralised HealthKit framework were explicitly withheld. The release of Google Health version 5.05 marks a strategic inflection point in cross-platform digital health infrastructure. Following the transition of the legacy Fitbit application into the consolidated Google Health platform—a migration accompanying the launch of the Fitbit Air device and the integration of Gemini-powered AI coaching, Google has instituted full bidirectional data synchronisation on iOS. This architectural shift enables metrics captured via Google hardware, including Fitbit trackers and Pixel Watches, to write directly into Apple’s HealthKit repository. The transition reflects a broader realignment in hardware and software monetisation. Rather than relying on closed data repositories to anchor users to specific smartphone platforms, digital health providers are shifting toward service-driven differentiation, algorithmic AI insights, and interoperable clinical data exchange. This report provides a technical and strategic evaluation of the Google Health 5.05 update, analysing its synchronisation architecture, data taxonomy, mathematical discrepancies in biometric calculations, clinical record mobility via Smart Health Links and long-term industry implications. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Technical Architecture of Google Health 5.05 Synchronisation Bidirectional Sync Mechanics and Integration Pathways Prior to version 5.05, the data exchange architecture between Google Health and Apple Health was strictly unidirectional. iPhone users running the Google Health app could import HealthKit data into Google’s cloud infrastructure to feed its analytics engines and AI Coach, but outbound data streams were restricted. Third-party bridging applications relied on periodic background fetches and legacy application programming interfaces (APIs), which frequently encountered iOS background execution limits, rate throttling, and incomplete metric translation. Under the version 5.05 architectural model, local biometric telemetry captured by hardware sensors, such as the Fitbit Air or Pixel Watch, is ingested by the local Google Health v5.05 application instance on iOS. Rather than transferring metrics strictly through remote cloud server synchronization, the Google Health application acts as a local client gateway that interfaces directly with Apple’s native HealthKit framework via system-level APIs. This enables bidirectional reading and writing operations between the isolated Google Health app database and the unified iOS HealthKit repository. System activation requires navigating to the user profile within Google Health, selecting the Partner Apps section, and authenticating Apple Health access. Upon authorization, Google Health requests read and write permissions across granular health categories. Upon initial linkage, the system executes a historical backfill, transferring approximately three months of historical Apple Health data into the Google Health environment, with expanding support planned for longer temporal windows. For outbound transfers, fitness activity, sleep telemetry, and vital signs recorded by Fitbit or Pixel Watch sensors are committed directly to the local HealthKit store on the iOS device. This native integration allows any third-party iOS application with HealthKit read access to consume hardware data gathered by Google wearables without requiring bespoke API integrations. Health Category Supported Metric Types Synchronization Directionality Outbound Availability (Google to Apple) Fitness & Activity Steps, Active Calories, Distance, Exercise Records, Workout Routes, Elevation/Floors, VO2 Max Bidirectional Supported Sleep Metrics Sleep Sessions, Sleep Stages (Light, Deep, REM), Restlessness, Naps Bidirectional Supported Vital Signs Resting Heart Rate, Continuous Heart Rate, Blood Oxygen Saturation ($SpO_2$), Respiratory Rate, Blood Glucose Bidirectional Supported Body Measurements Weight, Body Fat Percentage Bidirectional Supported Nutrition & Hydration Energy Intake, Macronutrients, Water Consumption, Custom Foods Bidirectional Supported Autonomic & Cardio Heart Rate Variability (HRV) Unidirectional / Restricted Not Supported Outbound Platform Bug Fixes and Performance Refinements In addition to expanding platform connections, version 5.05 addresses underlying algorithmic and rendering instabilities that affected earlier 5.0x iterations. Earlier releases introduced extended metric customisation on the Today tab, nap tracking integration into 24-hour sleep totals, and custom food entry tools. However, users encountered failures in post-workout map rendering, VO2 Max estimation drift, and transaction locks during post-hoc workout editing. Version 5.05 stabilises the calculation pipelines for cardiovascular metrics. VO2 Max (maximal oxygen consumption) estimation relies on relational modeling between submaximal heart rate, movement velocity derived from GPS, and user demographic baseline vectors. Google Health 5.05 resolves pipeline stalls where incomplete GPS maps caused anomalous VO2 Max outputs, ensuring data written to both internal databases and external HealthKit repositories remains consistent. Biometric Algorithmic Divergence: The HRV Exception Mathematical Incompatibility: RMSSD vs. SDNN Despite the broad categorisation of write-supported metrics, Heart Rate Variability (HRV) remains omitted from outbound synchronisation from Google Health to Apple Health. This omission stems from fundamental mathematical differences in how the two platforms quantify variations in autonomic nervous system tone and inter-beat (RR) intervals. Google Health and legacy Fitbit algorithms measure HRV primarily through the Root Mean Square of Successive Differences (RMSSD) between adjacent heartbeats. RMSSD reflects high-frequency beat-to-beat alterations, serving as a direct marker of parasympathetic (vagal) activity, particularly during sleep. Implications for Biometric Integrity Because RMSSD isolates short-term, high-frequency vagal fluctuations while SDNN captures total systemic variance across broader temporal frames, their numerical outputs cannot be mapped 1:1 without introducing biometric distortion. Writing an RMSSD-derived score (typically expressed in milliseconds, often yielding lower absolute values during periods of autonomic stress) into an Apple Health SDNN metric field would corrupt long-term baseline trends within Apple’s health algorithms, misrepresenting cardiovascular stress and recovery readiness. While both Apple HealthKit and Google Health APIs natively support the storage of both RMSSD and SDNN data types at the raw database tier, Google has opted to block outbound HRV transfers entirely in version 5.05. This prevents user confusion arising from conflicting recovery analytics, though it forces advanced users monitoring autonomic metrics to continue accessing HRV data directly within the native Google Health application interface. Clinical Data Mobility: Smart Health Links Architecture Implementation of Medical Record Summarisation Parallel to consumer fitness synchronization, Google Health 5.05 expands clinical data portability through the United States rollout of Smart Health Links. Built on open health data interoperability protocols, Smart Health Links allow users to compile scattered personal health records (PHRs)—including immunization logs, laboratory results, clinical encounter summaries, and medication lists—into secure, shareable artifacts. The architecture operates by indexing personal health records stored within the app’s Medical repository and packaging selected data subsets into an encrypted artifact. Once compiled, Google Health converts this payload into either a secure, short-lived uniform resource locator (URL) or a dynamic Quick Response (QR) code. Healthcare intake personnel or clinical systems can scan or navigate to this credentialed endpoint to pull the summarized clinical payload directly into provider intake software without establishing a permanent electronic health record (EHR) database link. Clinical Utility and Ecosystem Positioning Smart Health Links serve as a lightweight mechanism to streamline patient intake at clinical points of care, enabling patients to present a digital summary during registration rather than filling out paper questionnaires or navigating legacy patient portals. Google explicitly notes that Smart Health Links do not replace official clinical charts or formal Electronic Health Record (EHR) exchanges governed by healthcare regulations. However, when viewed alongside Apple’s native Health Records feature, which connects directly to health systems via Fast Healthcare Interoperability Resources (FHIR) APIs, Google’s approach offers a flexible, consumer-driven vector for sharing health summaries across varied healthcare settings. Feature Dimension Google Health Smart Health Links (v5.05) Apple Health Records Framework Primary Format Encrypted URL and dynamic QR Code summaries Direct OAuth2/FHIR EHR portal connections Geographic Availability United States Multi-region (US, UK, Canada, Australia) Data Ingestion Model User-selected data curation and manual uploads Automated background synchronization with clinical providers Primary Use Case Point-of-care intake, family sharing, transient provider access Long-term clinical history tracking, consolidated chart viewing Sharing Mechanism Ephemeral or managed web-based link access Device-to-device encrypted export or native app portal Platform Strategy, AI Workflows and Strategic Implications Transition from Hardware Lock-in to Ecosystem Accessibility The release of Google Health 5.05 reflects a broader shift in Google's digital health strategy. Historically, hardware manufacturers utilized proprietary data silos to tie consumers to specific hardware ecosystems. By permitting Fitbit devices to populate Apple Health natively, Google lowers the switching barrier for iPhone owners considering devices like the Fitbit Air or Pixel Watch. Consumers are no longer forced to choose between the hardware ergonomics of a Fitbit or Pixel Watch and the central data consolidation offered by iOS. The market trajectory leading to version 5.05 spans over a decade of strategic friction and realignment. When Apple introduced HealthKit alongside iOS 8 in 2014, Fitbit explicitly declined to support native data exports, opting instead to retain users within its proprietary ecosystem. Following Google’s acquisition announcement in 2019 and its formal completion in 2021, the platform embarked on a multi-year consolidation strategy. This phase involved sunsetting legacy web dashboards, enforcing Google Account authentication, and eventually rebranding the legacy Fitbit application to Google Health in early 2026. While version 5.0 initially introduced Gemini-powered AI coaching alongside read-only HealthKit capabilities, version 5.05 completes the transformation by enabling full bidirectional export, signalling a definitive pivot toward platform-agnostic health data services. This strategy positions Google’s wearable line as platform-agnostic health sensors. Monetisation shifts upstream from pure hardware sales toward software services, specifically Google Health Premium subscriptions that power Gemini AI coaching and predictive health modeling. Enterprise Extensions and Developer Workflows: The Google Health CLI To support data portability beyond consumer applications, Google has complemented its mobile platform updates with developer-focused tools, such as the Google Health Command Line Interface (CLI). The CLI allows developers, researchers, and advanced users to interact directly with health and wellness metrics managed by the Google Health API. The technical bridge relies on authorized OAuth2 authentication scopes to grant the CLI tool permission to query the Google Health API endpoint directly. The interface retrieves biometric streams from connected hardware, standardizes the raw values, and outputs structured data objects—such as JavaScript Object Notation (JSON) payloads, Comma-Separated Values (CSV) files, or formatted terminal tables. These structured outputs are optimized for consumption by automated scripts, data science pipelines, and local artificial intelligence agents tasked with advanced physiological modeling. By coupling local HealthKit synchronisation on iOS with programmatic API access via CLI tools, Google creates a dual-tier interoperability framework where HealthKit handles real-time consumer aggregation while API and CLI pathways support complex computational workflows. Synthesis and Recommendations The release of Google Health 5.05 resolves a decade-long ecosystem barrier, bringing bidirectional synchronisation to iPhone using Fitbit and Pixel Watch owners. By enabling direct write-backs to Apple HealthKit, Google neutralises a primary competitive disadvantage of its hardware portfolio on iOS while expanding the footprint of its health service layer. However, ongoing divergence in algorithmic methodologies, highlighted by the exclusion of HRV due to RMSSD versus SDNN structural differences, underscores the need for greater standardisation in digital biomarker processing. While data transport layers have become increasingly open, the interpretation layer remains fragmented by vendor-specific mathematical models. Strategic Recommendations for Industry Stakeholders Digital Health Developers and Software Vendors: Application developers leveraging HealthKit on iOS must audit input streams for data originating from Google Health, ensuring that metrics like workout records and sleep stages are deduplicated against native Apple Watch inputs. Systems reading autonomic health indicators must explicitly check the underlying sampling metadata, ensuring that RMSSD and SDNN values are not mixed within unified trend models. Healthcare Providers and Clinical Systems: Clinical intake workflows should be updated to accept Smart Health Link exports for US patients. Standardizing front-desk intake systems to scan these encrypted QR codes can accelerate patient registration and reduce manual entry errors. Clinical researchers should utilise developer frameworks, such as the Google Health CLI, to establish automated, user-consented data pipelines for remote patient monitoring studies. Enterprise Program Administrators and End Users: Corporate wellness platforms relying on Apple Health as a primary aggregation node can incorporate Fitbit hardware natively, expanding device choices for program participants. Multi-device users should manage category-level write permissions within the Partner Apps menu in Google Health to prevent duplicate step and activity counting across overlapping sensors. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Digital Health IPO Pipeline: Candidate Profiles, Market Mechanics and Valuation Realities Executive Summary The digital health sector enters late 2026 at a pivotal financial transition point. Following a multi-year liquidity drought, public capital markets briefly reopened in mid-2025, enabling a cohort of scaled healthtech companies, most notably Hinge Health, which raised $437 Million at a $2.6 Billion valuation on the NYSE and Omada Health, which raised $150 Million at a $1.1 Billion valuation on NASDAQ, alongside HeartFlow, Carlsmed and Profusa, to execute initial public offerings. Despite this breakthrough, the first half of 2026 experienced an operational freeze for core digital health listings, creating an acute exit backlog paradox where dozens of late-stage venture-backed unicorns face limited M&A avenues and must prepare for public listing scrutiny. Within this landscape, Oura Health stands as the definitive immediate frontrunner to become the next core digital health company to list publicly. In May 2026, Oura confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission. Backed by an $11.0 Billion valuation from its October 2025 Series E round, a projected 2026 revenue run rate between $1.5 Billion and $2.0 Billion and strong underlying profitability, Oura possesses the revenue scale, growth rate and financial discipline required by modern public equity markets. Directly behind Oura, a distinct pipeline of institutional candidates is executing structured pre-IPO maneuvers. Companies such as Spring Health, Zelis Healthcare, Virta Health, Abridge and Innovaccer are actively signalling public market readiness through confidential filings, senior public-market executive appointments, secondary liquidity tenders and large-scale strategic consolidations. Follow Nelson Advisors on LinkedIn https://www.linkedin.com/company/nelson-advisors Primary IPO Contender Profile: Oura Health Oura Health has transitioned from a consumer wellness wearable manufacturer into a clinical-grade diagnostic platform, positioning itself at the head of the digital health IPO pipeline. Its confidential Form S-1 submission in May 2026 followed a $900 Million Series E funding round in October 2025 led by Fidelity Management & Research Company, with participation from ICONIQ, Whale Rock Capital and Atreides Management. This transaction established Oura's private market valuation at $11.0 Billion, making it the highest-valued independent wearable technology platform globally. The company's operational trajectory displays rapid top-line growth coupled with improving unit economics. Oura generated over $500 Million in revenue in 2024 and doubled its top line to reach approximately $1.0 Billion in 2025. Executive guidance projects full-year 2026 revenue between $1.5 Billion and $2.0 Billion. At an $11.0 Billion private valuation, Oura trades at approximately 5.5 times projected 2026 sales, a reasonable forward multiple for a fast growing, profitable technology asset relative to historic bubble-era multiples. To lead its public debut, Oura assembled an underwriting syndicate composed of Goldman Sachs, Morgan Stanley, JPMorgan, Allen & Co and Jefferies. Oura's investment narrative centres on converting high volume consumer hardware distribution into high margin recurring software subscriptions and integrated clinical care workflows. Beyond tracking continuous baseline biometrics, Oura has expanded into enterprise clinical care ecosystems. Strategic integrations with continuous glucose monitoring leader Dexcom, alongside clinical partnerships with virtual care providers such as Midi Health, Evernow, Maven Clinic, and Progyny, position Oura as a foundational data layer within women's health, metabolic tracking, and cardiovascular care. Furthermore, specialised product features designed to monitor GLP-1 medication adherence, nighttime breathing, and cardiovascular load, supported by a proprietary population-specific AI model, provide a defensible data moat against competing hardware efforts from major consumer technology conglomerates. Near Term Pipeline: Institutional Contenders and S-1 Filings Beyond Oura, several institutional healthtech platforms have executed deliberate balance-sheet restructuring, executive hiring and corporate acquisition strategies to establish public listing readiness. Spring Health Spring Health has emerged as an advanced candidate within the employer and payer focused mental health market, currently covering more than 20 Million lives globally. Following a $100 Million Series E round that established its private valuation between $3.3 Billion and $4.0 Billion (bringing total capital raised to over $500 Million), leadership explicitly signalled that the capital was secured to fortify the company's balance sheet for a public listing. In a key operational step toward public governance, Spring Health appointed a Head of Investor Relations with extensive public company experience. Furthermore, Spring Health completed the strategic acquisition of clinician platform Alma in January 2026, creating a combined mental health enterprise targeting $1.0 Billion in total revenue in the year following merger completion. Backed by institutional investors including Kinnevik and Generation Investment Management, Spring Health possesses both the revenue scale and organisational structure necessary to execute an IPO. Zelis Healthcare Zelis Healthcare operates as a defensive healthcare FinTech and claims-payment clearinghouse platform, offering public equity markets exposure to healthcare IT infrastructure. Sponsored by Bain Capital and Parthenon Capital, Zelis is targeting an initial public offering with an anticipated valuation of approximately $17.0 Billion, supported by recent minority stake sales to sovereign wealth funds such as Mubadala. The company executed a confidential Form S-1 draft registration filing targeted for early 2026, engaging Goldman Sachs and JPMorgan as lead underwriters. Zelis enters the market with a robust balance sheet generating nearly $1.0 Billion in annual EBITDA, presenting a low-volatility cash-flow profile designed to appeal to institutional value and growth investors alike. Virta Health Virta Health specialises in Type 2 diabetes reversal and GLP-1 clinical medication management. CEO Sami Inkinen publicly stated that the company expects to be operationally IPO-ready in 2026. Virta surpassed $160 Million in annualised revenue in late 2025, maintaining a year-over-year top-line growth rate exceeding 80%. Last valued privately at $2.0 Billion following a $133 Million Series E funding round in 2021, Virta has repositioned its core technology to capture enterprise demand from self-insured employers and health plans seeking to control GLP-1 drug spending through structured clinical tapering protocols. Abridge Abridge has established itself as the leading generative AI clinical documentation platform in healthcare. Deployed across more than 150 health systems, including Johns Hopkins, Kaiser Permanente, Duke Health and the Mayo Clinic, Abridge processes over 50 Million medical conversations annually. A $300 Million Series E round in mid-2025 boosted the company's private valuation to $5.3 Billion. With high software gross margins, clear clinical ROI in reducing provider administrative burnout and rapid SaaS expansion, Abridge represents a prime candidate for an AI-native public stock listing. Innovaccer Innovaccer provides an enterprise data integration layer, known as the Healthcare Intelligence Cloud, for major health systems and managed care organisations. The company has sustained a 50% year-over-year revenue growth rate over five consecutive fiscal years while maintaining cash-flow positive operations. Valued at $3.45 Billion following a $275 Million Series F round, Innovaccer completed a $75 Million secondary ESOP buyback in January 2026. This secondary liquidity event enabled early employees and equity holders to monetise holdings while optimising the cap table, a standard operational milestone prior to filing a formal S-1 prospectus. Candidate Company Market Category Focus Private Valuation Benchmark Revenue Run-Rate / Scale Strategic Pre-IPO Status Zelis Healthcare Healthcare FinTech & Payments ~$17.0 Billion ~$1.0 Billion EBITDA Confidential S-1 Target Q1 2026; Underwriters Assigned Spring Health Workforce Mental Health $3.3B – $4.0B $1.0B Combined Run-Rate Target Public IR Executive Hired; Alma Acquisition Completed Abridge Clinical Generative AI $5.3 Billion 50M+ Annual Conversations Series E ($300M) Closed; Premier AI Listing Profile Innovaccer Healthcare Data Cloud $3.45 Billion Cash-Flow Positive; 50% YoY Growth Executed $75M Secondary ESOP Buyback (Jan 2026) Virta Health Metabolic Reversal & GLP-1 $2.0 Billion >$160M ARR late 2025 (80% YoY) Public CEO Statement for 2026 IPO Readiness Secondary Wave, Telehealth Transitions and Specialised Exits Behind the primary frontrunners, a second wave of private digital health platforms maintains the underlying revenue scale and market distribution required to enter the public market as liquidity conditions normalise. Direct to Consumer Telehealth Evolution Ro has evolved from a direct-to-consumer digital men's health provider into a vertically integrated telehealth infrastructure powerhouse. Financial data indicates Ro's revenue run rate grew from $185.3 Million in 2023 to $598 Million in 2024, with top-line momentum accelerating into 2026. This acceleration is anchored by direct-to-consumer partnerships with pharmaceutical manufacturers, including Novo Nordisk for branded oral Wegovy distribution, signaling a transition toward high-intent medical commerce. Last valued privately at $7.0 Billion in 2022, Ro offers a public peer comparison to Hims & Hers, though public investors will demand persistent revenue durability and expanding operating margins before supporting a listing. Similarly, Noom has restructured its business model ahead of a potential public debut. After shelving previous 2022 IPO plans led by Goldman Sachs, Noom achieved positive EBITDA, positive free cash flow, and a cash-rich balance sheet with zero debt. Driven by its GLP-1 Microdose clinical offering, which pairs low-dose compounded semaglutide with behavioral coaching and now accounts for 60% of top-line revenue—and enterprise partnerships with payers like Highmark Health, Noom has successfully diversified into recurring B2B payer revenue streams. Enterprise AI and Virtual Specialty Providers Commure has scaled rapidly within the clinical artificial intelligence and administrative automation space. Backed by a $70 Million Series D-3 funding round in May 2026 led by General Catalyst and Sequoia Capital, Commure achieved a private valuation of $7.0 Billion. The company generates $200 Million in annual recurring revenue while doubling its top-line sales year-over-year, targeting an initial public offering window between late 2026 and 2027. Sword Health operates as a cash-flow positive digital physical therapy provider and a direct competitor to Hinge Health. Generating a revenue run rate of $240 Million, Sword Health utilises its Phoenix AI agent to deliver autonomous clinical care. Although executive guidance points to a longer-term public timeline, secondary liquidity pressures from early venture holders could accelerate its public market debut. Maven Clinic continues to build its position as the largest virtual clinic dedicated to women's and family health, serving more than 23 Million covered lives across 2,000 corporate employers and health plans. Last valued at $1.7 Billion following a $125 Million Series F round led by StepStone Group, Maven appointed public-market executive leadership in 2025 to structure its internal operations for a public listing. Devoted Health combines a tech-enabled Medicare Advantage insurance plan with a virtual-first primary care delivery system. Having raised $2.3 Billion in venture capital with a private valuation reaching $12.6 Billion, Devoted Health represents a scaled, value-based care listing candidate. Lyra Health maintains a strong market presence in workforce mental health, covering 17 Million lives and generating an annualised revenue run rate of $235 Million. Valued between $5.5 Billion and $5.9 Billion, Lyra completed a $57 Million Series G funding round in June 2026 to accelerate clinical AI automation across its network of over 10,000 providers. Corporate Carve Outs, Mergers and Global Listings In addition to venture-backed primary listings, the public healthtech market is absorbing carved-out corporate entities, SPAC business combinations, and international offerings: Medtronic MiniMed, the automated insulin delivery and diabetes management spin-off of Medtronic, filed a Form S-1 registration statement in December 2025 under the ticker NASDAQ: MMED. The standalone pure-play entity generated ~$2.7 Billion in revenue for FY2025 and reported $128 Million in Adjusted EBITDA for the six months ended October 2025, with underwriting managed by Goldman Sachs, BofA Securities, Citigroup, and Morgan Stanley. Freenome, a developer of liquid biopsy multi-cancer early detection diagnostics, bypassed traditional draft filings by entering into a definitive business combination agreement with Perceptive Capital Solutions Corp under NASDAQ ticker FRNM. The transaction yields $330 Million in gross proceeds, establishing a post-merger enterprise value of ~$1.1 Billion. Molbio Diagnostics, an India-based molecular diagnostics developer known for its portable PCR Truenat platform, launched its public IPO in August 2026 on the NSE and BSE to raise Rs 939.70 crore. The company reported total income of Rs 1,455 crore (+42% YoY) and Profit After Tax of Rs 164 crore for FY26. Manipal Health Enterprises, one of India's largest healthcare network operators, completed a Rs 9,275.22 crore initial public offering in mid-2026, listing at an 11% premium on the BSE and NSE. Market Dynamics and Second Order Exit Mechanisms The structural environment surrounding the 2026 digital health IPO pipeline is shaped by capital allocation shifts, revised public market valuation frameworks, and operational leverage benchmarks. Venture Capital Concentration and Exit Backlog U.S. digital health venture capital funding rebounded to $14.2 Billion in 2025, representing a 35% increase over 2024's $10.5 Billion total. However, this headline growth concealed significant capital concentration. Mega-deals of $100 Million or more accounted for 42% to 45% of total capital deployed, while overall deal count dropped to 482. Removing the top nine capital raises from the 2025 data set drops total annual investment below 2024 levels, highlighting a funding environment focused heavily on proven late-stage platforms. This high concentration has created a structural exit bottleneck. Dozens of late-stage digital health platforms that raised capital at high valuations during the 2021 market peak cannot easily be acquired, as high capital costs and antitrust oversight limit corporate M&A transactions. Consequently, public equity markets represent the primary viable exit path for institutional investors seeking liquidity. Public Market Valuation Reset Public markets have recalibrated valuation models for digital health companies, moving away from speculative pandemic-era forward revenue multiples. Current public market pricing follows realistic operational tiers: Standard digital health platforms with non-differentiated virtual delivery models trade within a normalised multiple range of 4x to 6x forward revenue. Premium platforms featuring proprietary artificial intelligence engines, deep clinical workflow integrations, and validated health system data moats command valuation multiples of 6x to 8x+ revenue. Conversely, sub-scale or unprofitable platforms without demonstrated clinical outcomes face multiple compression down to 3x to 4x revenue, accelerating secondary corporate consolidation. Structural Efficiency and Revenue per Employee A defining operational benchmark for 2026 IPO candidates is productivity measured by revenue per Full-Time Equivalent employee. Traditional physical health service providers generate between $100,000 and $200,000 in revenue per FTE, while legacy healthcare SaaS vendors yield $200,000 to $400,000 per FTE. In contrast, AI-native infrastructure platforms such as Abridge and Commure generate between $500,000 and over $1,000,000 in revenue per FTE. By deploying AI to automate clinical documentation, prior authorisation and patient triage, these platforms decouple revenue scaling from linear head-count growth, unlocking structural operating leverage. Secondary Tenders and Private Crossover Strategies Because the primary IPO window remained selective through early 2026, late-stage crossover investors, including Fidelity, T. Rowe Price, Coatue and Wellington Management, are using secondary liquidity mechanisms. Rather than forcing premature public listings at discounted valuations, these institutions fund selective bridge rounds and execute structured tender offers, such as Innovaccer's $75 Million ESOP buyback and Oura's investor liquidity tenders. These transactions provide early liquidity while giving companies the time needed to optimise governance structures prior to formal public offerings. Digital Health IPO Pipeline: Candidate Profiles, Market Mechanics and Valuation Realities Comprehensive Candidate Landscape Analysis Primary Company Name Primary Sub-Sector Focus Private Valuation Benchmark Financial Scale & Key Metrics Form S-1 / Strategic Readiness Status Oura Health Wearable Diagnostic Platform $11.0 Billion $1.0B (2025 Rev); $1.5B–$2.0B (2026 Outlook) Form S-1 Confidential Draft Filed (May 2026) Zelis Healthcare Healthcare FinTech & Payments ~$17.0 Billion ~$1.0 Billion EBITDA Confidential S-1 Target Q1 2026 Medtronic MiniMed MedTech / Diabetes Spin-Off Multi-Billion ~$2.7B Rev; $128M Adj EBITDA Form S-1 Filed (Dec 2025); Ticker NASDAQ: MMED Spring Health Enterprise Mental Health $3.3B – $4.0B $1.0B Combined Run-Rate Target (Alma) Public IR Executive Hired; Explicit Balance Sheet Prep Commure Healthcare OS & AI Automation $7.0 Billion $200M ARR (Doubling YoY) Series D-3 Closed May 2026 ($70M); 2026/2027 Target Abridge Generative AI Clinical Notes $5.3 Billion 50M+ Conversations across 150 Systems Series E Closed ($300M); High-Margin SaaS Profile Innovaccer Data Integration Cloud $3.45 Billion Cash-Flow Positive; 50% YoY Growth $75M Secondary Buyback Completed (Jan 2026) Virta Health Metabolic Reversal & GLP-1 $2.0 Billion >$160M ARR late 2025 (80% YoY) Public CEO Target for 2026 IPO Readiness Ro Telehealth & GLP-1 Commerce $7.0 Billion $598M Revenue Run-Rate Active Partner Integration (Novo Nordisk); Target 2026/2027 Noom Behavioral Weight Management $3.7 Billion EBITDA / FCF Positive; Zero Debt Enterprise Shift Complete; GLP-1 Microdose Wedge Sword Health Digital Musculoskeletal Care Unspecified Growth $240M Revenue Run-Rate; Cash-Flow Positive Autonomous AI Care Delivery; Target Horizon 2026–2028 Maven Clinic Women's & Family Virtual Care $1.7 Billion 23M Covered Lives; 2,000+ Clients Senior Public Market Executive Appointments Devoted Health Medicare Advantage Tech $12.6 Billion $2.3B Total Venture Capital Raised Scaled Value-Based Care Listing Candidate Lyra Health Workforce Mental Health $5.5B – $5.9B $235M ARR; 17M Covered Lives $57M Series G Raised June 2026 Freenome Early Cancer Diagnostics $1.1 Billion (EV) $330M Expected Gross Proceeds Definitive SPAC Merger (NASDAQ: FRNM) Molbio Diagnostics Point-of-Care Molecular Dx ~$1.1 Billion Equivalent Rs 1,455 Cr FY26 Income; Rs 164 Cr PAT Public IPO Opening August 2026 (BSE / NSE) Conclusions and Strategic Outlook The analysis of regulatory filings, financial performance, and institutional capital flows confirms that Oura Health is positioned as the next core digital health platform to enter the public markets. Its confidential SEC Form S-1 submission, annual revenue scale approaching $2.0 Billion, high-margin subscription model, and expanding clinical footprint fulfil the rigorous criteria currently demanded by public equity underwriters. Directly following Oura, an established secondary cohort composed of Zelis Healthcare, Spring Health, Virta Health, Abridge, and Innovaccer forms a strong IPO candidate pipeline. Public market institutional investors evaluating this next wave of healthtech offerings will strictly enforce three core operational mandates: First, candidates must demonstrate clear near-term profitability, evidenced by positive EBITDA or sustainable free cash flow generation, as public markets no longer support growth-at-all-costs models. Second, platforms featuring AI-native workflow infrastructure, capable of achieving operational leverage exceeding $500,000 in revenue per full-time employee, will command premium valuation multiples relative to legacy virtual care providers. Third, companies with diversified B2B enterprise payer and employer contracts will be favoured over pure direct-to-consumer models due to lower customer acquisition costs and higher net revenue retention. As these financial standards take hold across private markets, the post-pandemic digital health backlog will transition into a durable, institutional public asset class. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

System C: Potential Acquirers The proposed sale of System C Healthcare by CVC Capital Partners, currently facilitated by the corporate finance advisory firm Arma Partners, marks a defining transaction in the mid-decade consolidation of the United Kingdom’s health and social care technology sectors. The asset, held under the parent entity Asclepius Topco Limited, has undergone a fundamental transformation since its acquisition from Symphony Technology Group in February 2021. At that time, the business was valued at an enterprise value exceeding 20x EV/EBITDA based on a trailing EBITDA of approximately £12 million. By the 2026 fiscal year, System C is projected to deliver an EBITDA of £46 million, reflecting a nearly four-fold increase in profitability under CVC’s stewardship based on a recent Mergermarket report. This trajectory is not merely a result of organic growth but is the culmination of a sophisticated "buy-and-build" strategy that has integrated specialised clinical capabilities in oncology, maternity and medicines management with a dominant market share in the social care and education software verticals. The divestiture process comes at a time when the UK’s National Health Service (NHS) is transitioning from its initial "Frontline Digitisation" phase toward an era of integrated care and "ambient" artificial intelligence. The market for Electronic Patient Records (EPR) has largely matured, with 97% of acute trusts in England expected to have a system in place by March 2026. Consequently, the value proposition for System C has shifted from being a provider of record-keeping software to a strategic data platform that bridges the traditionally siloed environments of acute hospitals and community based social care. This report explores the financial architecture of the transaction, the competitive landscape involving Oracle Health and Epic Systems, the strategic rationale for international expansion via the Australian provider MYP Technologies and the profiling of likely strategic and private equity acquirers in a market defined by high-recurring-revenue SaaS models and AI-driven efficiency mandates. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Financial Architecture and Valuation Modelling in the 2026 Exit Environment The financial performance of System C under CVC’s ownership provides a case study in margin expansion through vertical specialisation and technological modernisation. Financial filings for Asclepius Topco Limited show revenues of £107.2 million for the year ending March 31st, 2025. When viewed alongside the projected £46 million EBITDA for FY26, the company exhibits an EBITDA margin approaching 43%, a premium profile that reflects the high scalability of its cloud-native CareFlow and LiquidLogic platforms. The Evolution of Valuation Multiples The 2021 acquisition multiple of 20x EV/EBITDA was considered aggressive at the time, yet it was anchored in the mission-critical nature of the software and the low churn rates inherent in government-funded healthcare contracts. As Arma Partners brings the asset to market in 2026, the valuation will be judged against a higher EBITDA base but within a macroeconomic environment characterised by more disciplined capital allocation and a focus on "profitable efficiency". The resilience of data-driven businesses in the face of generative AI advancements, a trend highlighted by Arma Partners' own research, supports the maintenance of a premium multiple, as these platforms control the primary data sources required for AI implementation. Financial Metric FY2021 (Acquisition) FY2025 (Reported) FY2026 (Projected) Revenue ~£80 million £107.2 million ~£130 million (estimated) EBITDA £12 - £15 million ~£38 million (est.) £46 million (reported by Mergermarket) EBITDA Margin 15% - 18.7% ~35.4% ~35.4% - 43% Implied EV (at 20x) £240 - £300 million N/A £920 million Source: Mergermarket, 23rd Apr 2026, 'System C owner CVC appoints Arma Partners for sale of healthcare software firm' Revenue Quality and Retention Metrics A critical component of the valuation will be the quality of the recurring revenue. In the 2026 market, buyers are increasingly separating software acquisition costs from the total cost of transformation, including data remediation and adoption. System C’s revenue is characterised by: High Recurring Revenue Rate: Estimated at over 90%, consistent with leading peers like The Access Group and Dedalus. Low Customer Churn: Mission-critical EPR and social care systems typically experience churn rates below 2%, as the cost and clinical risk of replacement are prohibitive. Expansion Revenue: The ability to upsell modules such as the "FormFlow AI Assistant" to an existing base of 40 NHS hospitals and 60% of English councils. The integration of MYP Technologies in August 2025 adds an international dimension to the revenue profile. While the absolute revenue contribution of the Australian entity is smaller than the UK core, its role as a beachhead in the APAC region and a provider of 24/7 support capabilities enhances the "global platform" narrative, which typically commands a 2x to 3x turn multiple premium over domestic-only players. Product Ecosystem: Bridging the Acute-Social Care Divide System C’s competitive moat is built upon its "joined-up" digital strategy. While many competitors focus exclusively on the acute hospital environment, System C has built a dominant presence in the "back-office" and community sectors, which are increasingly recognised as the primary bottlenecks for healthcare efficiency. CareFlow: The Clinical and Acute Backbone The CareFlow EPR suite represents a modernized evolution of the legacy Medway system. It encompasses electronic patient records, patient flow management, and clinical communication. In 2026, the focus of CareFlow has shifted toward "ambient" clinical documentation. The acquisition of FormFlow AI has allowed System C to embed AI-driven assistants that help clinicians automate the recording of patient encounters, a move that directly addresses the 98% of social care professionals who identified administrative burden as a primary obstacle to care. The clinical depth of the CareFlow suite is further evidenced by its market leadership in specialised areas: Oncology: Through CIS Oncology, System C manages complex chemotherapy protocols for 80% of the UK market. Maternity: The BadgerNet platform provides a national contract in several regions, including New Zealand, ensuring that the company is deeply embedded in specialised clinical workflows that are difficult for "generalist" EPRs like Epic or Oracle to displace. Medicines Management: Managing over £9 billion in medications annually provides System C with a massive repository of prescribing data, which is a key asset for population health analytics and value-based procurement. Liquidlogic and the Social Care Nexus System C’s acquisition of Liquidlogic in 2009 was a visionary move that anticipated the current drive toward integrated care. Liquidlogic is now the market-leading solution for children’s and adults' social care in England. The strategic relevance of this cannot be overstated: as Integrated Care Systems (ICS) in England seek to manage "bed-blocking" and delayed discharges, the ability to have hospital systems (CareFlow) talk seamlessly to social care systems (Liquidlogic) becomes a "golden ticket" for operational efficiency. International Expansion and the MYP Technologies Acquisition The August 2025 acquisition of Australian peer MYP Technologies serves two primary strategic goals. First, it diversifies the company’s revenue away from the UK’s single-payer risk. Second, it brings specialised community-based and aged care management tech into the portfolio. MYP’s solutions are purpose-built for disability, allied health and aged care sectors that are seeing significant funding increases in Australia ($3 billion commitments) and Europe. Acquisition Target Date Strategic Value Liquidlogic 2009 Established 60% market share in UK social care. OCC 2023 Added integrated contracts and finance solutions for local government. CIS Oncology 2024 Secured 80% of the UK oncology software market. MYP Technologies Aug 2025 Internationalized the platform; added 24/7 global support. The Competitive Landscape: Consolidation and Challenger Dynamics The 2026 UK healthcare IT market is defined by a paradox: while most acute trusts have chosen an EPR, the market remains highly competitive as trusts look for "replacement" systems that offer better interoperability and lower total cost of ownership. The Oracle Health (Cerner) and Epic Dominance Oracle Health (formerly Cerner) remains the market leader in the UK, with approximately 25% of the acute EPR market. However, the company has faced significant headwinds. Oracle’s massive $28.3 billion acquisition of Cerner in 2022 has been followed by reports of financial strain, leading to rumors of a potential divestiture of the unit in 2026 to fund its $156 billion AI infrastructure commitments. Furthermore, Oracle executed significant layoffs on March 31, 2026, cutting an estimated 30% of its Revenue and Health Sciences division. This "talent window" has allowed competitors like System C and Nervecentre to poach experienced EHR specialists and implementation engineers. Epic Systems, by contrast, has seen the biggest gains in market share, rising to 9.7% of the UK market by 2025. Epic’s strategy focuses on "mega-trusts" and regional clusters, such as the £222 million contract for Somerset and Dorset. While Epic dominates the high end of the market, its high implementation costs and "closed ecosystem" perception leave significant room for more agile, cloud-native providers like System C. The Rise of Nervecentre Nervecentre has emerged as the fastest-growing EPR provider in the UK, recently becoming the second-largest supplier by hospital bed count. Nervecentre’s cloud-native platform is being adopted across regional clusters like Liverpool and the East Midlands, emphasising a "shared foundation" for regional transformation. The success of Nervecentre validates the market's appetite for SaaS-based, intuitive tools, a segment where System C’s CareFlow suite is also strongly positioned. Dedalus and the European Deleveraging Dedalus Group, once a dominant force in European health software, has focused on deleveraging and improving profitability in 2025 and 2026. With a market-leading position in DACH and Southern Europe, Dedalus is a formidable peer, but its "no acquisitions" stance through 2026, required to bring leverage down toward 8x EBITDA, effectively removes it as a likely bidder for System C. Strategic Acquirer Profiling: Who Will Buy System C? The "fireside chats" led by Arma Partners are likely engaging a mix of domestic strategic players, US based consolidators and large-scale private equity firms. 1. The Access Group The Access Group is perhaps the most logical strategic acquirer. With a valuation of over £9 billion and a mission focused on "empowering ambitious organisations" through cloud solutions, Access has a proven playbook for rapid M&A integration, having completed over 40 acquisitions in recent years. Strategic Fit: Access is heavily focused on HR, payroll and ERP, but its "Access Care & Clinical" solution for social care is a direct adjacency to System C’s Liquidlogic. The AI Angle: Access is aggressively rolling out its "Access Evo" AI platform. System C’s clinical and social care data would provide the essential training sets for Access to become a dominant AI player in the UK public sector. 2. IRIS Software Group IRIS Software Group has evolved from a specialist in accountancy and payroll into a diversified provider of mission-critical software for the public sector. Strategic Fit: IRIS already manages over 1,000,000 staff globally and pays one in six UK workers. Its specialised "IRIS GP Payroll" and accountancy software for healthcare organisations provide a natural "front-door" into the GP surgeries that must integrate with System C’s hospital and social care records. Consolidation Rationale: Acquiring System C would allow IRIS to bridge the gap between back-office financial management and front-line clinical delivery, creating a "total workforce and care management" platform. 3. Civica Civica is a UK-based public sector specialist that has historically grown through niche acquisitions like InfoFlex. Strategic Fit: Civica’s strength in local government and its existing presence in the health sector make it a natural contender. A merger with System C would create a "UK National Champion" in public service software, providing the scale needed to compete with US hyperscalers. 4. US-Based Hyperscalers and Strategic Bidders (Oracle, Microsoft, Amazon) While less likely to be direct bidders for a UK-centric asset, these firms influence the valuation ceiling: Oracle: If Oracle divests Cerner, it may ironically look to "buy back" into the UK market with a cleaner, more profitable asset like System C once its balance sheet is repaired. Microsoft: Operates as a "neutral infrastructure" layer via Azure and Nuance (DAX Copilot). An acquisition would jeopardise its status as the preferred partner for Epic and Meditech. 5. Private Equity (Thoma Bravo, Francisco Partners, Bain Capital, Hellman & Friedman etc..) Given the current market landscape in April 2026, System C’s reported £46 million EBITDA and its unique position in the UK's Integrated Care Systems (ICS) make it a "platform-grade" asset. While strategic buyers like The Access Group are in the mix, several large-cap US private equity firms have the specific "software + healthcare" mandate required to take over from CVC. Here are the primary US PE contenders: 1. Thoma Bravo Thoma Bravo is arguably the most aggressive US software investor. They specialize in high-margin, mission-critical enterprise software with "sticky" government or public sector contracts. The Play: They recently took Dayforce private for $12.3 billion (late 2025), showing a massive appetite for vertical-specific platforms. Why System C: They prioritise market leaders with high recurring revenue. System C’s dominance in UK social care (Liquidlogic) and its expansion into acute EPRs fit their "buy-and-build" playbook perfectly. They would likely use System C as a hub to acquire smaller European specialized health-tech firms. 2. Francisco Partners Francisco Partners has a dedicated healthcare technology team and a deep history in the UK (having previously owned assets like Zelis and invested in Availity). The Play: They closed a $2.2 billion acquisition of Jamf in late 2025 and have been active in the clinical data space with Avalon Healthcare Solutions. Why System C: Francisco Partners often targets companies at an inflection point. With the NHS pushing for "Federated Data Platforms," they could see System C as the bridge between clinical data and social care data—a high-value intersection for AI-driven health analytics. 3. Bain Capital Bain Capital’s healthcare team is one of the most active in Europe. They have a sophisticated understanding of the "Sponsor-to-Sponsor" (PE-to-PE) market. The Play: They were heavily involved in the 2025 European biopharma and provider surge (e.g., the STADA deal). Why System C: Bain often looks for "complex" integration plays. System C’s multi-pronged approach (hospital, social care, and pharmacy) is complex to manage but provides a massive "moat" against competitors. Bain has the operational resources to help System C expand into other highly regulated markets like Germany or the Nordics. 4. Hellman & Friedman (H&F) H&F typically targets "quality over quantity," preferring a few massive, market-dominating positions. The Play: They are currently investing from their tenth fund ($24bn+) and have a strong preference for software businesses with high barriers to entry. Why System C: If the valuation pushes toward the £1 billion mark (approx. 20-22x EBITDA), H&F is one of the few firms with the "deep pockets" and patience for a long-term hold in the regulated UK healthcare space. While CVC has significantly improved System C's margins (now roughly 35–43%), a US PE firm would likely focus on the "Data Value." In 2026, the value isn't just in the software; it's in the longitudinal patient record that System C controls across both the hospital and the home. System C: Potential Acquirers Market Drivers and Regulatory Headwinds: The 2026 Context The valuation of System C is fundamentally linked to the structural shifts within the NHS and the broader UK regulatory environment. The NHS 10-Year Plan and the "Left Shift" The UK’s health strategy is defined by the "Left Shift", moving care away from expensive hospital settings and into the community and the home. This shift directly benefits System C’s social care and community-focused portfolio (Liquidlogic and MYP). Technologies that facilitate remote patient monitoring (RPM) and community diagnostics are seeing faster adoption than traditional hospital-only tools . Value-Based Procurement and Clinical Validation Starting in early 2026, the NHS has enforced standardized "value-based procurement" guidance. This means that procurement decisions are no longer based on the "cheapest price" but on evidence of long-term patient outcomes and total pathway cost savings. System C’s deep clinical modules in oncology and maternity, which track outcomes over many years, provide the "clinical validation" that generic EPRs lack, making it a more resilient asset in a value-based market. The EHDS and the EU AI Act For international bidders, System C’s compliance with the European Health Data Space (EHDS) and the EU AI Act is a major selling point. The high cost of compliance with these regulations makes it difficult for new entrants to penetrate the European market, thereby increasing the scarcity value of established, compliant platforms like System C. The "EPR" Confusion: Packaging vs. Records A unique contextual factor in the 2026 market is the rollout of the "Extended Producer Responsibility" (EPR) for packaging in the UK. While this is a waste management regulation, it has created a broader demand for "traceability software" across all sectors, including healthcare. Companies like SAP and Workday are integrating these "packaging EPR" modules into their core platforms. A strategic acquirer from the ERP space might view System C as the "missing link" to provide total traceability for medical supplies and patient records in a unified system. Australia and New Zealand: The APAC Strategic Beachhead The acquisition of MYP Technologies is a response to the "Supply Gap" in the global health workforce. By 2030, the global healthcare workforce shortage is predicted to reach 11 million workers. Australia and New Zealand, with their aging populations and high healthcare spend, are key markets for automation technologies. Country Key Public Funding Commitment (2022-2025) Market Opportunity UK ~£9B (2025) for health/social care Integrated care and Frontline Digitisation. Australia ~A$3B (2022) for disability/aged care Community-based care and NDIS support. European Union ~€1.5B (2022) for digital health EHDS compliance and cross-border data. System C's presence in Australia, where it already holds national maternity and child protection contracts, allows it to offer a "global support model". For a US-based acquirer, this provides an immediate, ready-made international expansion vehicle that has already cleared the cultural and regulatory hurdles of the APAC region. Synthesis: The Value Proposition for an Acquirer The sale of System C is not merely the divestiture of a software company; it is the transfer of a strategic infrastructure asset that sits at the center of the UK’s integrated care ambitions. The value proposition for an acquirer is built on three recursive layers of value: Layer 1: The Defensive Core A highly profitable (£46M EBITDA), high-margin (~40%), and low-churn software business with a 90%+ recurring revenue rate. The mission-critical nature of the EPR and social care records ensures that cash flows are protected even in a downturn. Layer 2: The Synergistic Platform The unique "Acute + Social Care" combination. An acquirer like The Access Group or IRIS can leverage System C’s dominance in local government (60% share) to cross-sell a wide range of HR, payroll, and financial software. For an ICS, the "joined-up" record is a primary driver of cost savings, making System C the preferred partner for regional transformation. Layer 3: The AI and International Upside The potential to use System C’s massive, longitudinal data sets (oncology, maternity, medications) to train the next generation of "ambient clinical intelligence". The APAC presence via MYP Technologies provides the "exit ramp" for future growth beyond the UK, justifying a premium multiple in the 18x-22x range. Conclusions and Strategic Outlook As Arma Partners proceeds with the sale of System C, the transaction is expected to be one of the largest in the UK health-tech space in 2026. The projected enterprise value likely sits between £750 million and £900 Million, representing a significant return for CVC Capital Partners on their 2021 investment. The eventual winner of the process will likely be the firm that can best articulate a vision for "Total Integrated Care", one that utilises System C’s data richness to solve the systemic issues of workforce shortages and delayed hospital discharges. While private equity firms remain the most active buyers in the sub-£50m deal bracket, the scale and strategic importance of System C suggest that a large-scale strategic consolidator or a "mega-PE" fund looking for a platform for a global roll-up is the most probable outcome. Ultimately, the System C divestiture reflects a broader trend: in the 2026 health-tech market, the value has shifted from the software to the data and the workflow. The companies that control the clinical and social care record are the ones that will define the efficiency of the healthcare systems of the next decade. System C, with its unique vertical dominance and international footprint, is positioned at the very heart of this transformation. Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Oracle Cerner: Potential Acquirers of Oracle Health Evaluating Potential Successors for the Oracle Health Asset The global enterprise technology landscape in April 2026 is defined by a singular, overwhelming priority: the construction of the physical and cognitive infrastructure required to sustain the generative artificial intelligence revolution. For Oracle Corporation, a firm that has spent four decades transitioning from a relational database pioneer to a cloud applications giant, this priority has manifested as a "squeeze play" of historical proportions. As Oracle attempts to pivot toward becoming the premier "AI Infrastructure Landlord," it faces a liquidity and capital expenditure crisis that has placed its 2022 acquisition of Cerner, now Oracle Health, at the centre of divestiture speculation. The requirement to fund a $156 Billion infrastructure commitment for OpenAI, alongside massive contracts for Meta and Nvidia, has necessitated a brutal reevaluation of non-core assets. Identifying the most likely purchaser of the Cerner asset requires a nuanced understanding of the 2026 macroeconomic environment, the technical state of the platform and the strategic voids within the portfolios of Big Tech and Private Equity. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk The Infrastructure Paradox: Oracle’s Financial Position in 2026 To appreciate why a divestiture of Cerner is even being contemplated, one must analyse the radical shift in Oracle’s financial architecture. By the third quarter of fiscal year 2026, Oracle reported a staggering $553 Billion in Remaining Performance Obligations (RPO), a 325% increase year over year. While such a backlog typically signals a position of strength, the nature of these obligations, primarily long-term AI training contracts, requires a front loaded capital investment that the company's current balance sheet is struggling to support. Oracle has projected a $50 Billion capital expenditure budget for fiscal 2026, an amount that continues to climb as more AI contracts are finalised. The strain of this expansion led to the execution of the largest layoff in the company’s 47-year history on March 31st, 2026, with 30,000 workers displaced to free up an estimated $8 Billion to $10 Billion in cash flow. This reduction in force targeted nearly 18% of the global workforce, with the Oracle Health (Cerner) Revenue and Health Sciences (RHS) team seeing at least a 30% reduction. Despite these cuts, Oracle’s credit default swap (CDS) spreads have tripled and the company has resorted to requiring 40% upfront deposits from new customers to fund data centre construction. In this context, Cerner, which was acquired for $28.3 Billion, represents the most significant "lump sum" of liquidity available to the firm to service its $124 Billion debt load and fund GPU clusters. Deconstructing the Oracle Cerner Divestiture https://youtu.be/jYBTs_3Dsfo Oracle Corporation Financial Profile - Q3 Fiscal Year 2026 Metric Value ($ in Billions) Year-over-Year Growth Source Total Quarterly Revenue $17.2 22% Various Cloud Infrastructure (IaaS) Revenue $4.9 84% Various Remaining Performance Obligations (RPO) $553.0 325% Various Projected FY2026 CapEx $50.0 ~40% Revision Various Estimated Total Debt $124.0 N/A Various Operating Cash Flow (LTM) $23.5 13% Various Restructuring Budget (FY2026) $2.1 N/A Various The Cerner Asset in 2026: Value Proposition and Integration Risk The question of who will buy Cerner is inextricably linked to what the asset has become under Oracle’s stewardship. The rebranding to Oracle Health was intended to signal a fundamental shift from a legacy Electronic Health Record (EHR) provider to a cloud-native data platform. However, as of early 2026, the integration has been slower and more expensive than forecasted. While the launch of the "Clinical AI Agent" in early 2026 was a breakthrough, reportedly reducing physician paperwork by 40%, the platform has struggled with customer retention. According to KLAS research, Oracle Health has lost 57 acute care customers since 2022, including 12 systems with over 1,000 beds, as healthcare organisations cite poor partnership and a lack of follow through. Furthermore, the asset is heavily burdened by its commitment to the US Department of Veterans Affairs (VA) and Department of Defense (DoD) EHR modernisation projects. These federal contracts, while lucrative, have been plagued by delays, cost overruns and intense Congressional scrutiny, with new legislation in 2026 proposing "guardrails" that could prevent contract renewals if strict performance metrics are not met. Any buyer would be acquiring not only the Millennium and PowerChart IP but also a massive, mission-critical federal obligation that requires substantial engineering resources. EHR Market Share in Large US Health Systems (>10 Hospitals) - 2026 Vendor Market Share (%) Trend Since 2022 Source Epic Systems 48% Increasing Various Oracle Health (Cerner) 27% Decreasing Various MEDITECH 15% Stable Various Others 10% Consolidating Various The Strategic Suitors: Big Tech and the Data Moat The most prominent candidates for a Cerner acquisition are the "HyperScale" tech giants who view healthcare as the next multi trillion dollar frontier for AI application. Microsoft, Amazon and Google each possess the "deep pockets" required to fund such a transaction and the strategic motivation to integrate EHR data into their respective cloud ecosystems. Microsoft: The Integration and Intelligence Play Microsoft is frequently cited as the "prime suspect" for a Cerner acquisition. The strategic logic is compelling: Microsoft has already invested $16 billion in Nuance, the dominant player in the ambient scribe market, which has now evolved into the DAX Copilot tool used by over 600 health systems. Acquiring Cerner would allow Microsoft to move from being an "intelligence layer" that sits on top of EHRs to being the "operating system" for healthcare. However, Microsoft’s candidacy is complicated by its current relationship with Epic Systems. Epic, the market leader, currently runs its AI infrastructure and MyChart capabilities on Azure. If Microsoft were to acquire Cerner, Epic’s primary rival, it would jeopardise its "platform neutrality". Epic might view a Microsoft-owned Cerner as an existential threat, leading to a migration toward Google Cloud or AWS. Furthermore, given Microsoft’s existing dominance in healthcare AI, an acquisition of the second largest EHR player would almost certainly trigger a prolonged and aggressive antitrust challenge from the FTC. Amazon: The Vertical Integration and Distribution Play Amazon is the second primary strategic candidate, viewing Cerner through the lens of its broader healthcare ecosystem, which includes One Medical (primary care), Amazon Pharmacy and the newly launched "Agentic Health AI assistant".Amazon has demonstrated a willingness to pursue vertical integration and Cerner’s established customer base could serve as a powerful anchor for AWS healthcare infrastructure. An Amazon-owned Cerner would allow for seamless data flow between the hospital EHR, the One Medical primary care clinic, and the Amazon Pharmacy delivery system. This "unified patient 360-degree narrative" is a core goal of Amazon's strategy. Yet, Amazon faces similar challenges to Microsoft. AWS is the infrastructure provider for many healthcare entities, and owning a direct workflow owner like Cerner would fundamentally alter its posture from an "ecosystem power" to a "direct competitor". Amazon also lacks deep experience in operating regulated, mission-critical EHR infrastructure on the scale of the VA or major academic medical centers. Google: The Specialized AI and Data Play Google (Alphabet) is a candidate motivated by the need for high-quality, structured medical data to train its medical-specific AI models, such as Med-PaLM. Google has had a fragmented history in healthcare, shutting down Google Health in 2021, but it remains a "full war chest" player through Verily. For Google, Cerner would provide an "anchor" for its cloud ambitions and a way to compete with the Microsoft-Epic alliance. However, the "cultural mismatch" between Google’s rapid innovation cycle and the high-stakes, conservative environment of hospital clinical operations is a significant risk. Google also lacks the enterprise sales and support infrastructure that Oracle has spent years building, suggesting that a Google acquisition would likely lead to significant customer churn if execution faltered. The Private Equity Option: Turnaround, Carve Out and Financial Engineering If a sale to Big Tech is blocked by antitrust regulators or if the "neutrality" risk is deemed too high, a Private Equity (PE) consortium becomes the most viable alternative. Firms such as Thoma Bravo, Francisco Partners and Bain Capital are known for their ability to extract value from legacy tech assets through rigorous operational discipline and financial engineering. The Turnaround Thesis for Private Equity A PE buyer would likely view Cerner as a "classic turnaround" opportunity. Since 2022, Cerner has been managed as a vertical within a massive cloud conglomerate. A PE firm would likely "un-bundle" Cerner, separating the high-margin clinical IP from the lower-margin, high-friction consulting and implementation services. Key levers for a Private Equity buyer: SaaS Licensing Optimisation: Transitioning legacy customers to modern, higher-margin cloud-based licensing models more aggressively than Oracle has managed. Product Rationalization: End-of-lifing underperforming clinical modules and focusing engineering resources exclusively on the cloud-native "Next-gen EHR" that Oracle launched in 2025. The "Venture Capital" Model: Selling off specific components like consulting or support to specialized players while retaining the core patents and IP. Neutrality as a Competitive Edge: Unlike Microsoft or Amazon, a PE-owned Cerner would be "infrastructure agnostic," allowing it to run on OCI, AWS, or Azure, potentially winning back customers who were wary of Oracle "lock-in". Potential Private Equity Suitors and Strategic Rationale - 2026 Firm Recent Relevant Activity Strategic Logic for Cerner Source Thoma Bravo $12.3 Bn take-private of Dayforce Expert in "take-private" of mission-critical enterprise software. Various Francisco Partners $2.5 Bn acquisition of Jamf; previous Watson Health buy Focus on "carve-outs" and repositioning legacy health-tech assets. Various Bain Capital Healthcare-focused PE growth Turnaround thesis involving streamlining and refocusing go-to-market. Various Blackstone AGS Health (RCM) India IPO Interest in technology-enabled services and revenue cycle management. Various New Mountain Capital Created Machinify AI platform Building platforms that combine clinical data with payment integrity. Various The "dry powder" available to these firms is at a record $6 Trillion as of 2025 and healthcare IT deal value doubled in 2025 to approximately $32 Billion, suggesting that the capital for a $20Bn to $25Bn deal exists, though it would likely require a consortium. The Payers and Providers: Vertical Consolidation and Conflict of Interest A third category of potential buyers includes massive, diversified healthcare incumbents like UnitedHealth Group (UHG) or large hospital systems like HCA. This scenario represents the ultimate form of vertical integration, where the organisation that pays for or delivers care also owns the system that records it. UnitedHealth Group and Optum: The Data Mastery Scenario UHG’s Optum division has already pursued an aggressive "provider-payer-tech" strategy, acquiring physician groups, home health services (Amedisys), and revenue cycle management tools. Owning Cerner would provide Optum with direct access to core clinical workflows, enabling the "deep embedding" of prior authorisation tools and automated coding. However, the "conflict-of-interest" perception would be severe. If Optum owned Cerner, competing insurers (like Aetna or Cigna) and competing hospital systems would likely view the platform with extreme suspicion, fearing that UHG would use clinical data to gain a competitive advantage in the insurance market or to facilitate claim denials. Furthermore, the Department of Justice is already investigating UHG for antitrust violations related to its ownership of physician groups and insurers; adding a major EHR would likely be blocked on "vertical harm" grounds. Large Health Systems and Specialised Consortia There is a precedent for health systems taking control of their own technology, as seen with the formation of companies like Truveta for data sharing. A consortium of large hospital systems like HCA or CommonSpirit Health could theoretically acquire Cerner to "protect" their clinical infrastructure and ensure the platform’s survival. This move would be defensive, intended to prevent the platform from falling into the hands of a competitor (like Optum) or a distracted tech giant. Yet, the high capital requirements for AI modernisation make it unlikely that hospital systems, who are already facing margin pressure, would want to take on the $50 Billion CapEx cycle required for AI data centres. Oracle Cerner: Potential Acquirers of Oracle Health International Competitors: SAP and the European Foothold One outlier in the "likely buyer" discussion is SAP, the German enterprise software giant. SAP has a strong track record of acquiring competitors to diversify its offerings and has recently been aggressive in "secondary buyouts" from PE firms. An acquisition of Cerner by SAP would allow the firm to significantly increase its global outreach in healthcare, particularly in the Middle East and Europe, where Oracle has already made inroads through its "Sovereign Cloud" offerings. SAP’s expertise in ERP would allow it to integrate Cerner’s clinical data with administrative and financial systems, a strategy Oracle attempted but has struggled to execute perfectly. The Federal Factor: Why the Government Might Decide the Buyer In any divestiture scenario, the U.S. Federal Government is a "shadow participant" with veto power. Oracle’s contracts with the VA and DoD are among the largest in federal history, and the government has a vested interest in the stability and continuity of the EHR platform that serves millions of veterans. The VA "Guardrails" and Performance Leash By early 2026, the VA's EHR modernisation project had resumed after a series of disastrous installs were overhauls and tested. However, the program remains on a "two-year leash" under proposed legislation. If Oracle were to sell the EHR unit, the government would need to certify that the new owner has the technical capability and "sovereign-grade" infrastructure to handle the data of 150 million Americans. This federal oversight makes Big Tech buyers slightly more attractive to the government, as Microsoft and Amazon already have "FedRAMP High" authorised cloud environments, while Private Equity might be viewed with skepticism if the turnaround plan involves significant layoffs or offshoring of engineering talent. A buyer who cannot maintain the "FedRAMP High" security capabilities of OCI would likely be disqualified by federal regulators. Barriers to Transaction: Why Cerner Might Be "Hard to Sell" Despite the rumours, there are significant structural reasons why Cerner may remain under Oracle’s ownership or become "unsellable" at the price Oracle desires. The "Data Milk" vs. "The Cow" Argument Some industry analysts argue that Larry Ellison has already extracted the "data milk" he wanted from Cerner, the massive repositories of healthcare data used to train Oracle’s healthcare-specific LLMs and is now left with the "cow," an aging, debt-ridden software platform. If the IP has already been "harvested" and integrated into Oracle's broader AI offerings, the residual value of the Millennium platform may be significantly lower than the $28 Billion Oracle paid. Integration "Stickiness" and OCI Lock-in By early 2026, Oracle had successfully completed the migration of many Cerner workloads to OCI. This "deep integration" means that Cerner is no longer an independent application but is now reliant on the Oracle Autonomous Database and OCI networking. For a buyer to "un-wind" Cerner from OCI would be a massive technical undertaking, costing billions and potentially destabilising current hospital clients. This technical debt acts as a "poison pill," deterring strategic buyers who want to move the asset to their own cloud platforms. Potential Transaction Structures and Probability Assessment - April 2026 Structure Description Probability Key Risk Source Private Equity Consort. Majority stake to PE; Oracle retains minority and OCI hosting. High Governance complexity; PE exit cycle misalignment. Various Microsoft Strategic Buy Full acquisition to integrate with Nuance/Azure. Moderate Extreme antitrust scrutiny; loss of platform neutrality. Various Component Divestiture Selling services/support; keeping IP and Federal contracts. Moderate Finding a buyer for the "services-only" segment. Various Amazon Strategic Buy Integration with One Medical/Pharmacy. Low Cultural mismatch; lack of mission-critical EHR experience. Various SAP International Buy European-led acquisition for global expansion. Low Complexity of US federal contracts for a foreign firm. Various Macroeconomic Headwinds: The Financing Squeeze of 2026 The ability to sell Cerner is also constrained by the broader credit environment. Investment bank TD Cowen noted that "US banks have started pulling back their lending" for massive AI infrastructure projects. While Asian and foreign lenders are still providing capital, they have raised premiums to levels typically reserved for non-investment grade companies. For a PE consortium or a strategic buyer, financing a $20 Billion acquisition in this environment would be exceptionally expensive, potentially diluting the return on investment (ROI) to an unattractive level. Furthermore, Oracle’s stock has staged a recovery since March 2026, trading near $156 per share as investors begin to see the conversion of the $553 Billion RPO backlog into revenue. If Oracle can successfully "bridge" its liquidity crisis through the massive layoffs and the 40% upfront deposit requirements, the "necessity" of selling Cerner may diminish. Conclusion: The Likeliest Outcome for the Cerner Asset Based on the synthesis of market data, technical integration status and regulatory trends as of April 2026, the most likely path for the Cerner asset is not a clean, full-sum sale to Big Tech, but rather a complex carve-out involving Private Equity with Oracle maintaining a significant infrastructure "tail." A Private Equity consortium led by a firm like Thoma Bravo or Francisco Partners is the most probable successor. This structure satisfies several competing requirements: it provides Oracle with an immediate cash infusion to fund its GPU clusters (satisfying the liquidity crisis), it bypasses the most severe antitrust hurdles associated with a Microsoft or Amazon acquisition and it allows for a "neutral" platform that could potentially stabilise the customer base. Oracle would likely retain a minority interest and more importantly, a long-term hosting contract ensuring that Cerner continues to drive revenue for OCI, effectively "double-dipping" on both the sale and the subsequent infrastructure fees. Microsoft remains the secondary "most likely" candidate, but only if it can strike a deal with federal regulators and provide assurances to Epic Systems regarding Azure’s ongoing neutrality. Amazon and Google, while technically capable, appear increasingly unlikely as they focus their capital on internal "agentic AI" features rather than the heavy, regulated labour of legacy EHR management. Ultimately, the potential sale of Cerner represents more than just a corporate transaction; it is a signal of the end of the "Vertical SaaS" era for cloud providers and the beginning of the "Hyperscale Infrastructure" era. Oracle's transformation from a database giant to an "AI Infrastructure Landlord" may require the sacrifice of its largest acquisition, marking a definitive reset for the healthcare technology market and its 150 Million stakeholders. Nelson Advisors > European MedTech and HealthTech Investment Banking Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk #NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech Nelson Advisors LLP Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT lloyd@nelsonadvisors.co.uk paul@nelsonadvisors.co.uk Meet Nelson Advisors @ 2026 Events Digital Health Rewired > March 2026 > Birmingham, UK NHS ConfedExpo > June 2026 > Manchester, UK HLTH Europe > June 2026, Amsterdam, Netherlands HIMSS AI in Healthcare > July 2026, New York, USA Bits & Pretzels > September 2026, Munich, Germany World Health Summit 2026 > October 2026, Berlin, Germany HealthInvestor Healthcare Summit > October 2026, London, UK HLTH USA 2026 > October 2026, USA Barclays Health Elevate > October 2026, London, UK Web Summit 2026 > November 2026, Lisbon, Portugal MEDICA 2026 > November 2026, Düsseldorf, Germany Venture Capital World Summit > December 2026 Toronto, Canada Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk